Susan Halabi | Scholars@Duke

Susan Halabi
Professor of Biostatistics and Bioinformatics

Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.

Current Appointments & Affiliations

Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2012
Chief, Division of Biostatistics, Biostatistics & Bioinformatics, Basic Science Departments 2019
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1996

Contact Information

2424 Erwin Road 11th Floor, 11088 Hock Plaza, Durham, NC 27705
Duke Box 2717, Durham, NC 27710
susan.halabi@duke.edu (919) 681-5430
Prostate Cancer Nomograms for Predicting Overall Survival
curriculum vitae

Background
Education, Training, & Certifications
- Ph.D., University of Texas Health Sciences Center, Houston 1994
Duke Appointment History
- Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2005 - 2012
- Associate Professor in Surgery, Surgery, Urology, Surgery 2008 - 2011
- Assistant Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2000 - 2005
- Assistant Professor in Community and Family Medicine, Family Medicine and Community Health, Clinical Science Departments 1997 - 2000
- Instructor, Temporary in the Department of Community and Family Medicine, Family Medicine and Community Health, Clinical Science Departments 1996 - 1997
Recognition
In the News
- JUN 4, 2018 Duke Health News
  
  Survival Benefit for African-Americans with Advanced Prostate Cancer
- MAR 9, 2016 Stat News
  
  When prostate cancer spreads, where it goes matters
- MAR 8, 2016
  
  Where Prostate Cancer Spreads In the Body Affects Survival Time
- OCT 20, 2013
  
  New prognostic model predicts survival in advanced prostate cancer
Awards & Honors
Expertise
Subject Headings
Global Scholarship
- Research
  - Peru (Country)
  - United States of America (Country)
Research
Selected Grants
- Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC awarded by National Institutes of Health 2020 - 2025
- Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer awarded by National Institutes of Health 2019 - 2024
- Duke CTSA (TL1) awarded by National Institutes of Health 2018 - 2023
- Role of oncogenic phosphorylated MED1 in aggressive prostate cancer awarded by National Institutes of Health 2017 - 2022
- HOXB13 as a therapeutic target in prostate cancer awarded by Prostate Cancer Foundation 2020 - 2022
- Surrogate Endpoints of Overall Survival in Men with Metastatic Hormone Sensitive Prostate Cancer awarded by Prostate Cancer Foundation 2018 - 2021
- HERO Program, HERO Registry, HERO-HCQ Trial awarded by Patient Centered Outcomes Research Institute 2020 - 2021
- PCRP Clinical Consortium: Duke University Clinical Research Site awarded by Department of Defense 2007 - 2021
- Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer awarded by Department of Defense 2018 - 2021
- Translational Research in Surgical Oncology awarded by National Institutes of Health 2002 - 2021
- Statistical Analysis of CTC enumeration and neuroendocrine cell features in the PROPHECY trial (NCT02269982) awarded by Epic Sciences, Inc 2020
- Health Disparity in African Americans: A Meta-analysis of Six Phase III Trials in Metastatic Castration-Resistant Prostate Cancer Men treated with Docetaxel awarded by Department of Defense 2015 - 2020
- Precision Medicine in Platinum-treated Lethal Bladder Cancer awarded by Memorial Sloan-Kettering Cancer Center 2017 - 2020
- Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) awarded by Prostate Cancer Foundation 2014 - 2020
- Serum Androgens and Survival in CRPC awarded by University of California - San Francisco 2015 - 2018
- Administrative Supplement to Study Mechanisms of Cancer Sensitivity and Resistance to Therapy Utilizing Samples and Information from Human Clinical Trials - CALGB 90203 awarded by Brigham and Women's Hospital 2016 - 2018
- Optimizing First Line Treatment for Men with Castrate Resistant Prostate Cancer awarded by Prostate Cancer Foundation 2015 - 2018
- National Clinical Trials Network - Network Group Statistics and DMCs awarded by Mayo Clinic 2014 - 2017
- Validation of prognostic and pathway signatures in lethal prostate cancer awarded by National Institutes of Health 2011 - 2017
- Developing and Validating Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate Cancer awarded by National Institutes of Health 2011 - 2016
- Expression Profiling of Renal Cell Carcinoma Utilizing Tissue from CALGB 90206 awarded by Cedars Sinai Medical Center 2012 - 2015
- Predictive Markers in Metastatic Renal Cancer awarded by University of California - San Francisco 2013 - 2014
- Cancer and Leukemia Group B Statistical Center awarded by National Institutes of Health 1982 - 2010
- Telomerase RNA Transfected Dendritic Cell Vaccines awarded by National Institutes of Health 2002 - 2006
External Relationships
- American Society of Clinical Oncology
- Bayer
- Eisai
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Casey, Michelle, Evgeny Degtyarev, María José Lechuga, Paola Aimone, Alain Ravaud, Robert J. Motzer, Feng Liu, et al. “Estimand framework: Are we asking the right questions? A case study in the solid tumor setting.” Pharm Stat, November 5, 2020. https://doi.org/10.1002/pst.2079.
    Full Text Link to Item
  - Halabi, Susan, Sandipan Dutta, Yuan Wu, and Aiyi Liu. “Score and deviance residuals based on the full likelihood approach in survival analysis.” Pharm Stat 19, no. 6 (November 2020): 940–54. https://doi.org/10.1002/pst.2047.
    Full Text Link to Item
  - Fisher, Julie G., David Tait, Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Julian C. Schink, Ricardo H. Alvarez, et al. “Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” Target Oncol, October 22, 2020. https://doi.org/10.1007/s11523-020-00753-7.
    Full Text Link to Item
  - Al Baghdadi, Tareq, Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Patricia Rich, Eugene R. Ahn, Seungjean Chai, et al. “Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” Target Oncol, October 17, 2020. https://doi.org/10.1007/s11523-020-00752-8.
    Full Text Link to Item
  - Zhang, Wei, Aiyi Liu, Zhiwei Zhang, Tonja Nansel, and Susan Halabi. “Best (but oft-forgotten) practices: sample size and power calculation for a dietary intervention trial with episodically consumed foods.” Am J Clin Nutr 112, no. 4 (October 1, 2020): 920–25. https://doi.org/10.1093/ajcn/nqaa176.
    Full Text Link to Item
  - Eastham, James A., Glenn Heller, Susan Halabi, J Paul Monk, Himisha Beltran, Martin Gleave, Christopher P. Evans, et al. “Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.” J Clin Oncol 38, no. 26 (September 10, 2020): 3042–50. https://doi.org/10.1200/JCO.20.00315.
    Full Text Link to Item
  - Xie, Wanling, Meredith M. Regan, Marc Buyse, Susan Halabi, Philip W. Kantoff, Oliver Sartor, Howard Soule, et al. “Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.” J Clin Oncol 38, no. 26 (September 10, 2020): 3032–41. https://doi.org/10.1200/JCO.19.03114.
    Full Text Link to Item
  - Halabi, S. “Pan-cancer prognostic models of clinical outcomes: statistical exercise or clinical tools?” Ann Oncol, September 3, 2020. https://doi.org/10.1016/j.annonc.2020.08.2233.
    Full Text Link to Item
  - Halabi, S., S. Dutta, C. M. Tangen, M. Rosenthal, D. P. Petrylak, I. M. Thompson, K. N. Chi, et al. “Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer.” Ann Oncol 31, no. 7 (July 2020): 930–41. https://doi.org/10.1016/j.annonc.2020.03.309.
    Full Text Link to Item
  - Ryan, Charles J., Sandipan Dutta, William K. Kelly, Rob Middleberg, Carly Russell, Michael J. Morris, Mary-Ellen Taplin, Susan Halabi, and Susan Alliance for Clinical Trials in Oncology Genitourinary Committee. “Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel.” Clin Genitourin Cancer 18, no. 3 (June 2020): 222-229.e2. https://doi.org/10.1016/j.clgc.2019.10.002.
    Full Text Link to Item
  - Gupta, Santosh, Daniel H. Hovelson, Gabor Kemeny, Susan Halabi, Wen-Chi Foo, Monika Anand, Jason A. Somarelli, et al. “Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.” Genes, Chromosomes & Cancer 59, no. 4 (April 2020): 225–39. https://doi.org/10.1002/gcc.22824.
    Full Text
  - Halabi, Susan, Sandipan Dutta, Catherine M. Tangen, Mark Rosenthal, Daniel P. Petrylak, Ian M. Thompson, Kim N. Chi, et al. “Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel.” Jnci Cancer Spectr 4, no. 2 (April 2020): pkaa003. https://doi.org/10.1093/jncics/pkaa003.
    Full Text Link to Item
  - Sugimoto, Tomoyuki, Toshimitsu Hamasaki, Scott R. Evans, and Susan Halabi. “Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes.” Lifetime Data Anal 26, no. 2 (April 2020): 266–91. https://doi.org/10.1007/s10985-019-09470-4.
    Full Text Link to Item
  - Balogh, Erin P., Andrew B. Bindman, S Gail Eckhardt, Susan Halabi, R Donald Harvey, Ishmael Jaiyesimi, Rebecca Miksad, et al. “Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs.” Oncologist 25, no. 3 (March 2020): e405–11. https://doi.org/10.1634/theoncologist.2019-0698.
    Full Text Link to Item
  - George, Daniel J., Susan Halabi, Patrick Healy, Darius Jonasch, Monika Anand, Julia Rasmussen, Sarah Y. Wood, Charles Spritzer, John F. Madden, and Andrew J. Armstrong. “Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.” Urologic Oncology 38, no. 3 (March 2020): 79.e15-79.e22. https://doi.org/10.1016/j.urolonc.2019.08.015.
    Full Text
  - Ryan, Charles J., Sandipan Dutta, William K. Kelly, Carly Russell, Eric J. Small, Michael J. Morris, Mary-Ellen Taplin, Susan Halabi, and Susan From The Alliance for Clinical Trials in Oncology Genitourinary Committee. “Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).” Prostate Cancer Prostatic Dis 23, no. 1 (March 2020): 66–73. https://doi.org/10.1038/s41391-019-0152-3.
    Full Text Link to Item
  - Ahn, E. R., P. K. Mangat, E. Garrett-Mayer, S. Halabi, E. G. Dib, D. E. Haggstrom, K. B. Alguire, et al. “Palbociclib in patients with non–small-cell lung cancer with cdkn2a alterations: results from the targeted agent and profiling utilization registry study.” Jco Precision Oncology 4 (January 1, 2020): 757–66. https://doi.org/10.1200/PO.20.00037.
    Full Text
  - Armstrong, Andrew J., Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Z. Szmulewitz, Daniel C. Danila, Patrick Healy, et al. “Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.” Jco Precis Oncol 4 (2020). https://doi.org/10.1200/PO.20.00200.
    Full Text Link to Item
  - Halabi, Susan, and Simon Day. “Improved Reporting in Abstracts When Uncertainty Is Inevitable.” Jama Netw Open 2, no. 12 (December 2, 2019): e1917543. https://doi.org/10.1001/jamanetworkopen.2019.17543.
    Full Text Link to Item
  - George, Daniel J., Susan Halabi, Patrick Healy, Ian Barak, Carolyn Winters, Monika Anand, Rhonda Wilder, et al. “Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.” Prostate 79, no. 15 (November 2019): 1752–61. https://doi.org/10.1002/pros.23899.
    Full Text Link to Item
  - Armstrong, Andrew J., Susan Halabi, Jun Luo, David M. Nanus, Howard I. Scher, Emmanuel S. Antonarakis, and Daniel J. George. “Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.” J Clin Oncol 37, no. 24 (August 20, 2019): 2184–86. https://doi.org/10.1200/JCO.19.01230.
    Full Text Link to Item
  - Dess, Robert T., Holly E. Hartman, Brandon A. Mahal, Payal D. Soni, William C. Jackson, Matthew R. Cooperberg, Christopher L. Amling, et al. “Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.” Jama Oncol 5, no. 7 (July 1, 2019): 975–83. https://doi.org/10.1001/jamaoncol.2019.0826.
    Full Text Link to Item
  - Hussain, A., R. J. Lee, J. N. Graff, and S. Halabi. “The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone.” Crit Rev Oncol Hematol 139 (July 2019): 108–16. https://doi.org/10.1016/j.critrevonc.2019.04.020.
    Full Text Link to Item
  - Armstrong, Andrew J., Susan Halabi, Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Z. Szmulewitz, Daniel C. Danila, et al. “Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.” J Clin Oncol 37, no. 13 (May 1, 2019): 1120–29. https://doi.org/10.1200/JCO.18.01731.
    Full Text Link to Item
  - Mohler, James L., Susan Halabi, Stephen T. Ryan, Ali Al-Daghmin, Mitchell H. Sokoloff, Gary D. Steinberg, Ben L. Sanford, et al. “Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series.” Prostate Cancer Prostatic Dis 22, no. 2 (May 2019): 309–16. https://doi.org/10.1038/s41391-018-0106-1.
    Full Text Link to Item
  - Tierney, Jayne F., Claire L. Vale, Wendy R. Parelukar, Larysa Rydzewska, and Susan Halabi. “Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer.” Eur Urol Focus 5, no. 2 (March 2019): 137–43. https://doi.org/10.1016/j.euf.2019.01.005.
    Full Text Link to Item
  - Xie, Wanling, Susan Halabi, Jayne F. Tierney, Matthew R. Sydes, Laurence Collette, James J. Dignam, Marc Buyse, Christopher J. Sweeney, and Meredith M. Regan. “A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses.” Jnci Cancer Spectr 3, no. 1 (March 2019): pkz002. https://doi.org/10.1093/jncics/pkz002.
    Full Text Link to Item
  - Halabi, Susan, Sandipan Dutta, Catherine M. Tangen, Mark Rosenthal, Daniel P. Petrylak, Ian M. Thompson, Kim N. Chi, et al. “Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.” J Clin Oncol 37, no. 5 (February 10, 2019): 403–10. https://doi.org/10.1200/JCO.18.01279.
    Full Text Link to Item
  - Armstrong, Andrew J., Santosh Gupta, Patrick Healy, Gabor Kemeny, Beth Leith, Michael R. Zalutsky, Charles Spritzer, et al. “Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.” Plos One 14, no. 5 (January 2019): e0216934. https://doi.org/10.1371/journal.pone.0216934.
    Full Text
  - Halabi, Susan, Cai Li, and Sheng Luo. “Developing and Validating Risk Assessment Models of Clinical Outcomes in Modern Oncology.” Jco Precis Oncol 3 (2019). https://doi.org/10.1200/PO.19.00068.
    Full Text Open Access Copy Link to Item
  - Ma, Hua, Susan Halabi, and Aiyi Liu. “On the use of min-max combination of biomarkers to maximize the partial area under the ROC curve.” J Probab Stat 2019 (2019). https://doi.org/10.1155/2019/8953530.
    Full Text Link to Item
  - Choueiri, Toni K., Colin Hessel, Susan Halabi, Ben Sanford, M Dror Michaelson, Olwen Hahn, Meghara Walsh, et al. “Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].” Eur J Cancer 103 (November 2018): 287. https://doi.org/10.1016/j.ejca.2018.09.022.
    Full Text Link to Item
  - Li, Megan, Flora Mulkey, Chen Jiang, Bert H. O’Neil, Bryan P. Schneider, Fei Shen, Paula N. Friedman, et al. “Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).” Clin Cancer Res 24, no. 19 (October 1, 2018): 4734–44. https://doi.org/10.1158/1078-0432.CCR-17-1523.
    Full Text Link to Item
  - Choueiri, Toni K., Colin Hessel, Susan Halabi, Ben Sanford, M Dror Michaelson, Olwen Hahn, Meghara Walsh, et al. “Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.” Eur J Cancer 94 (May 2018): 115–25. https://doi.org/10.1016/j.ejca.2018.02.012.
    Full Text Link to Item
  - Anderson, Kenneth, Nofisat Ismaila, Patrick J. Flynn, Susan Halabi, Sundar Jagannath, Mohammed S. Ogaily, Jim Omel, et al. “Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 36, no. 8 (March 2018): 812–18. https://doi.org/10.1200/jco.2017.76.6402.
    Full Text
  - Gillessen, Silke, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Alberto Bossi, Rob Bristow, Brett Carver, et al. “Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.” Eur Urol 73, no. 2 (February 2018): 178–211. https://doi.org/10.1016/j.eururo.2017.06.002.
    Full Text Link to Item
  - “Editorial Board for The 2015 International Society for Biopharmaceutical Statistics (ISBS) and DIA China Special Issue.” Statistics in Biopharmaceutical Research 10, no. 1 (January 2, 2018): 70–70. https://doi.org/10.1080/19466315.2018.1451706.
    Full Text
  - Armstrong, A. J., E. S. Antonarakis, M. -. E. Taplin, W. K. Kelly, H. Beltran, K. Fizazi, W. L. Dahut, et al. “Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.” Ann Oncol 29, no. 1 (January 1, 2018): 23–25. https://doi.org/10.1093/annonc/mdx648.
    Full Text Link to Item
  - Mangat, Pam K., Susan Halabi, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, Ajjai Alva, Katherine A. Janeway, Philip J. Stella, et al. “Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” Jco Precision Oncology 2018 (January 2018). https://doi.org/10.1200/po.18.00122.
    Full Text
  - Pi, Lira, and Susan Halabi. “Combined Performance of Screening and Variable Selection Methods in Ultra-High Dimensional Data in Predicting Time-To-Event Outcomes.” Diagn Progn Res 2 (2018). https://doi.org/10.1186/s41512-018-0043-4.
    Full Text Link to Item
  - Mahar, Alyson L., Carolyn Compton, Susan Halabi, Kenneth R. Hess, Martin R. Weiser, and Patti A. Groome. “Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes.” J Surg Oncol 116, no. 8 (December 2017): 969–82. https://doi.org/10.1002/jso.24774.
    Full Text Link to Item
  - Xie, Wanling, Meredith M. Regan, Marc Buyse, Susan Halabi, Philip W. Kantoff, Oliver Sartor, Howard Soule, et al. “Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.” J Clin Oncol 35, no. 27 (September 20, 2017): 3097–3104. https://doi.org/10.1200/JCO.2017.73.9987.
    Full Text Link to Item
  - Choueiri, Toni K., Susan Halabi, Michael J. Morris, and Daniel George. “Reply to B. Rini et al and S. Buti et al.” J Clin Oncol 35, no. 16 (June 1, 2017): 1859–60. https://doi.org/10.1200/JCO.2017.72.2629.
    Full Text Link to Item
  - Choueiri, Toni K., Susan Halabi, Ben L. Sanford, Olwen Hahn, M Dror Michaelson, Meghara K. Walsh, Darren R. Feldman, et al. “Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.” J Clin Oncol 35, no. 6 (February 20, 2017): 591–97. https://doi.org/10.1200/JCO.2016.70.7398.
    Full Text Link to Item
  - Zhang, Qiang, Boris Freidlin, Edward L. Korn, Susan Halabi, Sumithra Mandrekar, and James J. Dignam. “Comparison of futility monitoring guidelines using completed phase III oncology trials.” Clin Trials 14, no. 1 (February 2017): 48–58. https://doi.org/10.1177/1740774516666502.
    Full Text Link to Item
  - Lin, Chen-Yen, and Susan Halabi. “A Simple Method for Deriving the Confidence Regions for the Penalized Cox's Model via the Minimand Perturbation.” Commun Stat Theory Methods 46, no. 10 (2017): 4791–4808. https://doi.org/10.1080/03610926.2015.1085568.
    Full Text Link to Item
  - Hertz, Daniel L., Kouros Owzar, Sherrie Lessans, Claudia Wing, Chen Jiang, William Kevin Kelly, Jai Patel, et al. “Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.” Clin Cancer Res 22, no. 19 (October 1, 2016): 4890–4900. https://doi.org/10.1158/1078-0432.CCR-15-2823.
    Full Text Link to Item
  - Xie, W., C. Sweeney, M. Regan, M. Nakabayashi, M. Buyse, N. Clarke, L. Collette, et al. “Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP).” Annals of Oncology 27 (October 1, 2016): vi243. https://doi.org/10.1093/annonc/mdw372.01.
    Full Text
  - Kattan, Michael W., Kenneth R. Hess, Mahul B. Amin, Ying Lu, Karl G. M. Moons, Jeffrey E. Gershenwald, Phyllis A. Gimotty, et al. “American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine.” Ca: A Cancer Journal for Clinicians 66, no. 5 (September 2016): 370–74. https://doi.org/10.3322/caac.21339.
    Full Text
  - Mahar, Alyson L., Carolyn Compton, Susan Halabi, Kenneth R. Hess, Jeffrey E. Gershenwald, Richard A. Scolyer, and Patti A. Groome. “Critical Assessment of Clinical Prognostic Tools in Melanoma.” Ann Surg Oncol 23, no. 9 (September 2016): 2753–61. https://doi.org/10.1245/s10434-016-5212-5.
    Full Text Link to Item
  - McEwen, Abigail R., Heileen Hsu-Kim, Nicholas A. Robins, Nicole A. Hagan, Susan Halabi, Olivo Barras, Daniel deB Richter, and John J. Vandenberg. “Residential metal contamination and potential health risks of exposure in adobe brick houses in Potosí, Bolivia.” Sci Total Environ 562 (August 15, 2016): 237–46. https://doi.org/10.1016/j.scitotenv.2016.03.152.
    Full Text Open Access Copy Link to Item
  - Halabi, Susan, William Kevin Kelly, Hua Ma, Haojin Zhou, Nicole C. Solomon, Karim Fizazi, Catherine M. Tangen, et al. “Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 34, no. 14 (May 2016): 1652–59. https://doi.org/10.1200/jco.2015.65.7270.
    Full Text
  - Scher, Howard I., Michael J. Morris, Walter M. Stadler, Celestia Higano, Ethan Basch, Karim Fizazi, Emmanuel S. Antonarakis, et al. “Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.” J Clin Oncol 34, no. 12 (April 20, 2016): 1402–18. https://doi.org/10.1200/JCO.2015.64.2702.
    Full Text Link to Item
  - Armstrong, A. J., P. Healy, S. Halabi, R. Vollmer, A. Lark, G. Kemeny, K. Ware, and S. J. Freedland. “Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.” Prostate Cancer and Prostatic Diseases 19, no. 1 (March 2016): 40–45. https://doi.org/10.1038/pcan.2015.46.
    Full Text Open Access Copy
  - Armstrong, Andrew J., Susan Halabi, Tim Eisen, Samuel Broderick, Walter M. Stadler, Robert J. Jones, Jorge A. Garcia, et al. “Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.” The Lancet. Oncology 17, no. 3 (March 2016): 378–88. https://doi.org/10.1016/s1470-2045(15)00515-x.
    Full Text
  - Kim, Sangjin, and Susan Halabi. “High Dimensional Variable Selection with Error Control.” Biomed Res Int 2016 (2016): 8209453. https://doi.org/10.1155/2016/8209453.
    Full Text Open Access Copy Link to Item
  - ICECaP Working Group, Brandon, Christopher Sweeney, Mari Nakabayashi, Meredith Regan, Wanling Xie, Julia Hayes, Nancy Keating, et al. “The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).” J Natl Cancer Inst 107, no. 12 (December 2015): djv261. https://doi.org/10.1093/jnci/djv261.
    Full Text Link to Item
  - Kim, Hyung L., Susan Halabi, Ping Li, Greg Mayhew, Jeff Simko, Andrew B. Nixon, Eric J. Small, et al. “A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).” Ebiomedicine 2, no. 11 (November 2015): 1814–20. https://doi.org/10.1016/j.ebiom.2015.09.012.
    Full Text Link to Item
  - Mahar, Alyson L., Carolyn Compton, Lisa M. McShane, Susan Halabi, Hisao Asamura, Ramon Rami-Porta, Patti A. Groome, and Patti A. Molecular Modellers Working Group of American Joint Committee on Cancer. “Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools.” J Thorac Oncol 10, no. 11 (November 2015): 1576–89. https://doi.org/10.1097/JTO.0000000000000652.
    Full Text Link to Item
  - Gillessen, S., A. Omlin, G. Attard, J. S. de Bono, E. Efstathiou, K. Fizazi, S. Halabi, et al. “Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.” Ann Oncol 26, no. 8 (August 2015): 1589–1604. https://doi.org/10.1093/annonc/mdv257.
    Full Text Link to Item
  - Potthoff, Richard F., and Susan Halabi. “A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.” Pharm Stat 14, no. 4 (July 2015): 273–83. https://doi.org/10.1002/pst.1683.
    Full Text Link to Item
  - Becker, Andreas, Christian Eichelberg, and Maxine Sun. “Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?” Cancer 121, no. 11 (June 1, 2015): 1906–7. https://doi.org/10.1002/cncr.29255.
    Full Text Link to Item
  - Hagan, Nicole, Nicholas Robins, Heileen Hsu-Kim, Susan Halabi, Ruben Dario Espinoza Gonzales, Enrique Ecos, Daniel Richter, and John Vandenberg. “Mercury hair levels and factors that influence exposure for residents of Huancavelica, Peru.” Environ Geochem Health 37, no. 3 (June 2015): 507–14. https://doi.org/10.1007/s10653-014-9665-9.
    Full Text Link to Item
  - Halabi, Susan, Brian I. Rini, Bernard Escudier, Walter M. Stadler, and Eric J. Small. “Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?” Cancer 121, no. 11 (June 1, 2015): 1906. https://doi.org/10.1002/cncr.29252.
    Full Text Link to Item
  - Armstrong, Andrew J., and Susan Halabi. “Making progress on progression in metastatic prostate cancer.” J Clin Oncol 33, no. 12 (April 20, 2015): 1322–24. https://doi.org/10.1200/JCO.2014.59.4283.
    Full Text Link to Item
  - Patel, Jai N., Chen Jiang, Daniel L. Hertz, Flora A. Mulkey, Kouros Owzar, Susan Halabi, Mark J. Ratain, et al. “Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).” Cancer 121, no. 7 (April 1, 2015): 1025–31. https://doi.org/10.1002/cncr.29169.
    Full Text Link to Item
  - Bitting, Rhonda L., Patrick Healy, Susan Halabi, Daniel J. George, Michael Goodin, and Andrew J. Armstrong. “Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.” Urol Oncol 33, no. 3 (March 2015): 110.e1-110.e9. https://doi.org/10.1016/j.urolonc.2014.09.002.
    Full Text Link to Item
  - Sartor, Oliver, and Susan Halabi. “Independent data monitoring committees: an update and overview.” Urol Oncol 33, no. 3 (March 2015): 143–48. https://doi.org/10.1016/j.urolonc.2014.12.013.
    Full Text Link to Item
  - Moser, Barry Kurt, and Susan Halabi. “Sample Size Requirements and Study Duration for Testing Main Effects and Interactions in Completely Randomized Factorial Designs When Time to Event is the Outcome.” Commun Stat Theory Methods 44, no. 2 (2015): 275–85. https://doi.org/10.1080/03610926.2012.705940.
    Full Text Link to Item
  - Smith, Matthew R., Susan Halabi, and Eric J. Small. “Reply to F. Valcamonico et al.” J Clin Oncol 32, no. 32 (November 10, 2014): 3685. https://doi.org/10.1200/JCO.2014.57.3808.
    Full Text Link to Item
  - Halabi, S., H. Zhou, E. J. Small, N. C. Solomon, A. J. Armstrong, L. Shen, S. Oudard, O. Sartor, and J. S. de Bono. “795PA PROGNOSTIC MODEL FOR PREDICTING RADIOGRAPHIC PROGRESSION- FREE SURVIVAL (RPFS) IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER MEN TREATED WITH SECOND-LINE CHEMOTHERAPY.” Ann Oncol 25, no. suppl_4 (September 1, 2014): iv276. https://doi.org/10.1093/annonc/mdu336.43.
    Full Text Link to Item
  - Liu, Chunling, Aiyi Liu, Jiang Hu, Vivian Yuan, and Susan Halabi. “Adjusting for misclassification in a stratified biomarker clinical trial.” Stat Med 33, no. 18 (August 15, 2014): 3100–3113. https://doi.org/10.1002/sim.6164.
    Full Text Link to Item
  - “ERRATA.” Journal of Clinical Oncology 32, no. 13 (May 1, 2014): 1387–1387. https://doi.org/10.1200/jco.2014.56.5366.
    Full Text
  - Smith, Matthew R., Susan Halabi, Charles J. Ryan, Arif Hussain, Nicholas Vogelzang, Walter Stadler, Ralph J. Hauke, et al. “Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).” J Clin Oncol 32, no. 11 (April 10, 2014): 1143–50. https://doi.org/10.1200/JCO.2013.51.6500.
    Full Text Link to Item
  - Halabi, S. “Erratum.” Jnci Journal of the National Cancer Institute 106, no. 4 (April 8, 2014): dju096–dju096. https://doi.org/10.1093/jnci/dju096.
    Full Text
  - Halabi, Susan, Chen-Yen Lin, W Kevin Kelly, Karim S. Fizazi, Judd W. Moul, Ellen B. Kaplan, Michael J. Morris, and Eric J. Small. “Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.” J Clin Oncol 32, no. 7 (March 1, 2014): 671–77. https://doi.org/10.1200/JCO.2013.52.3696.
    Full Text Link to Item
  - Halabi, Susan, Brian Rini, Bernard Escudier, Walter M. Stadler, and Eric J. Small. “Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.” Cancer 120, no. 1 (January 1, 2014): 52–60. https://doi.org/10.1002/cncr.28221.
    Full Text Link to Item
  - Armstrong, Andrew J., Tong Shen, Susan Halabi, Gabor Kemeny, Rhonda L. Bitting, Patricia Kartcheske, Elizabeth Embree, et al. “A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.” Clin Genitourin Cancer 11, no. 4 (December 2013): 397–406. https://doi.org/10.1016/j.clgc.2013.05.007.
    Full Text Link to Item
  - Halabi, Susan, Chen-Yen Lin, Eric J. Small, Andrew J. Armstrong, Ellen B. Kaplan, Daniel Petrylak, Cora N. Sternberg, et al. “Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.” J Natl Cancer Inst 105, no. 22 (November 20, 2013): 1729–37. https://doi.org/10.1093/jnci/djt280.
    Full Text Link to Item
  - Lin, Chen-Yen, and Susan Halabi. “On model specification and selection of the Cox proportional hazards model.” Stat Med 32, no. 26 (November 20, 2013): 4609–23. https://doi.org/10.1002/sim.5876.
    Full Text Link to Item
  - Halabi, Susan, Andrew J. Armstrong, Oliver Sartor, Johann de Bono, Ellen Kaplan, Chen-Yen Lin, Nicole C. Solomon, and Eric J. Small. “Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.” J Clin Oncol 31, no. 31 (November 1, 2013): 3944–50. https://doi.org/10.1200/JCO.2013.50.3201.
    Full Text Link to Item
  - Aggarwal, Rahul, Susan Halabi, William Kevin Kelly, Daniel George, John F. Mahoney, Frederick Millard, Walter M. Stadler, et al. “The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).” Cancer 119, no. 20 (October 15, 2013): 3636–43. https://doi.org/10.1002/cncr.28285.
    Full Text Link to Item
  - Apolo, Andrea B., Irina Ostrovnaya, Susan Halabi, Alexia Iasonos, George K. Philips, Jonathan E. Rosenberg, Jamie Riches, Eric J. Small, Matthew I. Milowsky, and Dean F. Bajorin. “Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.” J Natl Cancer Inst 105, no. 7 (April 3, 2013): 499–503. https://doi.org/10.1093/jnci/djt015.
    Full Text Link to Item
  - Armstrong, Andrew J., Daniel J. George, and Susan Halabi. “Reply to M A Khattak et al.” J Clin Oncol 31, no. 7 (March 1, 2013): 972–73. https://doi.org/10.1200/JCO.2012.47.7224.
    Full Text Link to Item
  - Lin, C. Y., E. J. Small, A. J. Armstrong, E. B. Kaplan, D. P. Petrylak, C. N. Sternberg, L. Shen, S. Oudard, J. S. De Bono, and A. O. Sartor. “A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.” J Clin Oncol 31, no. 6_suppl (February 20, 2013): 24. https://doi.org/10.1200/jco.2013.31.6_suppl.24.
    Full Text Link to Item
  - Hagan, Nicole, Nicholas Robins, Heileen Hsu-Kim, Susan Halabi, Ruben Dario Espinoza Gonzales, Daniel deB Richter, and John Vandenberg. “Residential mercury contamination in adobe brick homes in Huancavelica, Peru.” Plos One 8, no. 9 (2013): e75179. https://doi.org/10.1371/journal.pone.0075179.
    Full Text Link to Item
  - Atkinson, Thomas M., Susan Halabi, Antonia V. Bennett, Lauren Rogak, Laura Sit, Yuelin Li, Ellen Kaplan, Ethan Basch, and Ethan Cancer and Leukemia Group B. “Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903.” Pain Med 13, no. 11 (November 2012): 1417–24. https://doi.org/10.1111/j.1526-4637.2012.01498.x.
    Full Text Link to Item
  - Armstrong, Andrew J., Daniel J. George, and Susan Halabi. “Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.” J Clin Oncol 30, no. 27 (September 20, 2012): 3402–7. https://doi.org/10.1200/JCO.2011.40.9631.
    Full Text Link to Item
  - Monk, J Paul, Susan Halabi, Joel Picus, Arif Hussain, George Philips, Ellen Kaplan, Tim Ahles, et al. “Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.” Cancer 118, no. 17 (September 1, 2012): 4139–47. https://doi.org/10.1002/cncr.26732.
    Full Text Link to Item
  - Robins, Nicholas A., Nicole Hagan, Susan Halabi, Heileen Hsu-Kim, Ruben Dario Espinoza Gonzales, Mark Morris, George Woodall, et al. “Estimations of historical atmospheric mercury concentrations from mercury refining and present-day soil concentrations of total mercury in Huancavelica, Peru.” Sci Total Environ 426 (June 1, 2012): 146–54. https://doi.org/10.1016/j.scitotenv.2012.03.082.
    Full Text Link to Item
  - Halabi, Susan. “Adjustment on the Type I Error Rate for a Clinical Trial Monitoring for both Intermediate and Primary Endpoints.” J Biom Biostat 7 (May 19, 2012): 15. https://doi.org/10.4172/2155-6180.S7-015.
    Full Text Link to Item
  - Kelly, William Kevin, Susan Halabi, Michael Carducci, Daniel George, John F. Mahoney, Walter M. Stadler, Michael Morris, et al. “Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.” J Clin Oncol 30, no. 13 (May 1, 2012): 1534–40. https://doi.org/10.1200/JCO.2011.39.4767.
    Full Text Link to Item
  - Atkinson, Thomas M., Eric J. Small, Lauren Rogak, Laura Sit, Natalie Barragan, Mary Shaw, Liora Pollick, et al. “MEASUREMENT OF AFFECTIVE AND ACTIVITY PAIN INTERFERENCE USING THE BRIEF PAIN INVENTORY.” Annals of Behavioral Medicine 43 (April 1, 2012): S222–S222.
    Link to Item
  - Armstrong, Andrew J., Mario A. Eisenberger, Susan Halabi, Stephane Oudard, David M. Nanus, Daniel P. Petrylak, A Oliver Sartor, and Howard I. Scher. “Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.” Eur Urol 61, no. 3 (March 2012): 549–59. https://doi.org/10.1016/j.eururo.2011.11.009.
    Full Text Link to Item
  - Korn, Edward L., Boris Freidlin, Jeffrey S. Abrams, and Susan Halabi. “Design issues in randomized phase II/III trials.” J Clin Oncol 30, no. 6 (February 20, 2012): 667–71. https://doi.org/10.1200/JCO.2011.38.5732.
    Full Text Link to Item
  - Halabi, S., W. K. Kelly, E. B. Kaplan, and E. J. Small. “Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” J Clin Oncol 30, no. 5_suppl (February 10, 2012): 200.
    Link to Item
  - Harzstark, A. L., S. Halabi, W. K. Kelly, M. J. Morris, P. G. Febbo, and E. J. Small. “Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy.” J Clin Oncol 30, no. 5_suppl (February 10, 2012): 129.
    Link to Item
  - Harzstark, Andrea Lynne, Susan Halabi, William Kevin Kelly, Michael J. Morris, Phillip G. Febbo, and Eric Jay Small. “Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy.” Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 129–129. https://doi.org/10.1200/jco.2012.30.5_suppl.129.
    Full Text
  - Moser, Barry Kurt, and Susan Halabi. “Estimation and testing of the relative risk of disease in case-control studies with a set of k matched controls per case with known prevalence of disease.” Stat Med 31, no. 1 (January 13, 2012): 29–44. https://doi.org/10.1002/sim.4414.
    Full Text Link to Item
  - Hurwitz, Mark D., Susan Halabi, Laura Archer, Lamar S. McGinnis, Michael R. Kuettel, Steven J. DiBiase, and Eric J. Small. “Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809.” Cancer 117, no. 24 (December 15, 2011): 5579–88. https://doi.org/10.1002/cncr.26203.
    Full Text Link to Item
  - Liu, C., A. Liu, and S. Halabi. “A min-max combination of biomarkers to improve diagnostic accuracy.” Statistics in Medicine 30, no. 27 (November 30, 2011): 3266. https://doi.org/10.1002/sim.4317.
    Full Text
  - Liu, Chunling, Aiyi Liu, and Susan Halabi. “A min-max combination of biomarkers to improve diagnostic accuracy.” Stat Med 30, no. 16 (July 20, 2011): 2005–14. https://doi.org/10.1002/sim.4238.
    Full Text Link to Item
  - George, D. J., S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, et al. “Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 4664.
    Link to Item
  - Halabi, S., W. K. Kelly, D. J. George, M. J. Morris, E. B. Kaplan, and E. J. Small. “Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC).” Journal of Clinical Oncology 29, no. 7_suppl (March 1, 2011): 189–189. https://doi.org/10.1200/jco.2011.29.7_suppl.189.
    Full Text
  - Halabi, S., W. K. Kelly, D. J. George, M. J. Morris, E. B. Kaplan, and E. J. Small. “Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC).” J Clin Oncol 29, no. 7_suppl (March 2011): 189.
    Link to Item
  - Shapiro, C. L., S. Halabi, V. Hars, L. Archer, D. Weckstein, J. Kirshner, W. Sikov, et al. “Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.” Eur J Cancer 47, no. 5 (March 2011): 683–89. https://doi.org/10.1016/j.ejca.2010.11.024.
    Full Text Link to Item
  - Picus, Joel, Susan Halabi, W Kevin Kelly, Nicholas J. Vogelzang, Young E. Whang, Ellen B. Kaplan, Walter M. Stadler, Eric J. Small, and Eric J. Cancer and Leukemia Group B. “A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.” Cancer 117, no. 3 (February 1, 2011): 526–33. https://doi.org/10.1002/cncr.25421.
    Full Text Link to Item
  - Hagan, N., N. Robins, H. Hsu-Kim, S. Halabi, M. Morris, G. Woodall, T. Zhang, A. Bacon, D. D. B. Richter, and J. Vandenberg. “Estimating historical atmospheric mercury concentrations from silver mining and their legacies in present-day surface soil in Potosí, Bolivia.” Atmospheric Environment 45, no. 40 (January 1, 2011): 7619–26. https://doi.org/10.1016/j.atmosenv.2010.10.009.
    Full Text
  - Stadler, Walter M., George Phillips, Daniel J. George, Susan Halabi, and Eric Small. “Bevacizumab and everolimus in renal cancer: a rational way forward.” J Clin Oncol 28, no. 33 (November 20, 2010): e692–93. https://doi.org/10.1200/JCO.2010.30.7934.
    Full Text Link to Item
  - Garber, Judy E., Susan Halabi, Sara M. Tolaney, Ellen Kaplan, Laura Archer, James N. Atkins, Stephen Edge, et al. “Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.” J Natl Cancer Inst 102, no. 13 (July 7, 2010): 942–49. https://doi.org/10.1093/jnci/djq211.
    Full Text Link to Item
  - Kelly, W. K., S. Halabi, M. A. Carducci, D. J. George, J. F. Mahoney, W. M. Stadler, M. J. Morris, P. W. Kantoff, J. P. Monk, and E. J. Small. “A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401.” Journal of Clinical Oncology 28, no. 18_suppl (June 20, 2010): LBA4511–LBA4511. https://doi.org/10.1200/jco.2010.28.18_suppl.lba4511.
    Full Text
  - Kelly, W. K., S. Halabi, M. A. Carducci, D. J. George, J. F. Mahoney, W. M. Stadler, M. J. Morris, et al. “A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401.” J Clin Oncol 28, no. 18_suppl (June 20, 2010): LBA4511.
    Link to Item
  - Armstrong, Andrew J., George J. Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia A. Creel, Kelly Mundy, et al. “A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.” Clin Cancer Res 16, no. 11 (June 1, 2010): 3057–66. https://doi.org/10.1158/1078-0432.CCR-10-0124.
    Full Text Link to Item
  - Armstrong, A. J., D. J. George, and S. Halabi. “Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTor inhibition in patients with metastatic renal cell carcinoma (RCC).” Journal of Clinical Oncology 28, no. 15 (May 20, 2010).
    Link to Item
  - Armstrong, A. J., G. Kemeny, J. D. Turnbull, C. Chao, C. Winters, Y. A. Fesko, D. A. Bradley, S. Halabi, D. J. George, and M. Garcia-Blanco. “Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): TPS249–TPS249. https://doi.org/10.1200/jco.2010.28.15_suppl.tps249.
    Full Text
  - Halabi, S., B. I. Rini, W. M. Stadler, and E. J. Small. “Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).” Journal of Clinical Oncology 28, no. 15 (May 20, 2010).
    Link to Item
  - Gulley, James L., Philip M. Arlen, Ravi A. Madan, Kwong-Yok Tsang, Mary P. Pazdur, Lisa Skarupa, Jacquin L. Jones, et al. “Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.” Cancer Immunol Immunother 59, no. 5 (May 2010): 663–74. https://doi.org/10.1007/s00262-009-0782-8.
    Full Text Link to Item
  - Rini, Brian I., Susan Halabi, Jonathan E. Rosenberg, Walter M. Stadler, Daniel A. Vaena, Laura Archer, James N. Atkins, et al. “Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.” J Clin Oncol 28, no. 13 (May 1, 2010): 2137–43. https://doi.org/10.1200/JCO.2009.26.5561.
    Full Text Link to Item
  - Halabi, Susan, and Kouros Owzar. “The importance of identifying and validating prognostic factors in oncology.” Semin Oncol 37, no. 2 (April 2010): e9-18. https://doi.org/10.1053/j.seminoncol.2010.04.001.
    Full Text Link to Item
  - Sartor, Oliver, David G. McLeod, Susan Halabi, Paul F. Schellhammer, Peter T. Scardino, Anthony V. D’Amico, Charles Bennett, John T. Wei, and John T. COMPARE Registry Steering Committee. “The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.” Urology 75, no. 3 (March 2010): 623–29. https://doi.org/10.1016/j.urology.2009.04.059.
    Full Text Link to Item
  - Armstrong, Andrew J., Ian F. Tannock, Ronald de Wit, Daniel J. George, Mario Eisenberger, and Susan Halabi. “The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.” Eur J Cancer 46, no. 3 (February 2010): 517–25. https://doi.org/10.1016/j.ejca.2009.11.007.
    Full Text Link to Item
  - Regan, M. M., E. K. O’Donnell, W. K. Kelly, S. Halabi, W. Berry, S. Urakami, N. Kikuno, and W. K. Oh. “Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.” Ann Oncol 21, no. 2 (February 2010): 312–18. https://doi.org/10.1093/annonc/mdp308.
    Full Text Link to Item
  - Hagan, N., N. Robins, H. Hsu-Kim, S. Halabi, M. Morris, G. Woodall, T. Zhang, A. Bacon, D. D. B. Richter, and J. Vandenberg. “Estimating historical atmospheric mercury concentrations from silver mining and their legacies in present-day surface soil in Potosí, Bolivia.” Atmospheric Environment, 2010.
  - Bajorin, Dean F., Susan Halabi, and Eric Small. “Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).” Clin Genitourin Cancer 7, no. 3 (October 2009): E66–70. https://doi.org/10.3816/CGC.2009.n.026.
    Full Text Link to Item
  - Fitzpatrick, J. M., C. N. Sternberg, F. Saad, M. Extermann, O. Caffo, S. Halabi, G. Kramer, S. Oudard, and R. de Wit. “Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment.” European Urology, Supplements 8, no. 9 (September 1, 2009): 738–46. https://doi.org/10.1016/j.eursup.2009.06.001.
    Full Text
  - Rini, B. I., S. Halabi, J. E. Rosenberg, B. Escudier, A. Pluzanska, P. Koralewski, and S. Hotte. “Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Update (vol 3, pg 200, 2009).” Cuaj Canadian Urological Association Journal 3, no. 4 (August 2009): 289–289.
    Link to Item
  - Rini, B. I., S. Halabi, J. Rosenberg, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czaykowski, J. Dutcher, and E. J. Small. “Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.” J Clin Oncol 27, no. 18_suppl (June 20, 2009): LBA5019.
    Link to Item
  - Halabi, Susan, Nicholas J. Vogelzang, San-San Ou, Kouros Owzar, Laura Archer, and Eric J. Small. “Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.” J Clin Oncol 27, no. 17 (June 10, 2009): 2766–71. https://doi.org/10.1200/JCO.2008.18.9159.
    Full Text Link to Item
  - Philips, G. K., S. Halabi, B. L. Sanford, D. Bajorin, E. J. Small, and E. J. Cancer and Leukemia Group B. “A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.” Ann Oncol 20, no. 6 (June 2009): 1074–79. https://doi.org/10.1093/annonc/mdn749.
    Full Text Link to Item
  - Armstrong, A. J., S. Halabi, I. F. Tannock, D. J. George, R. DeWit, and M. Eisenberger. “Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 5137.
    Link to Item
  - Halabi, S., O. Sartor, D. Petrylak, C. N. Sternberg, J. A. Witjes, M. Noursalehi, T. J. McKearn, and M. J. George. “Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 5150.
    Link to Item
  - Luu, T., O. Sartor, N. Dandade, S. Halabi, and C. Bennett. “Comparability of health-related quality of life (HRQOL), treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy (HT) versus observation (OBS): Results from the COMPARE registry.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 5131.
    Link to Item
  - Rini, B. I., S. Halabi, J. Rosenberg, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czaykowski, J. Dutcher, and E. J. Small. “Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): LBA5019.
    Link to Item
  - Sartor, A. O., D. Petrylak, C. Sternberg, F. Witjes, S. Halabi, W. Berry, M. Petrone, T. McKearn, M. Noursalehi, and M. George. “Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 5148.
    Link to Item
  - Bennett, Charles L., Oliver Sartor, Susan Halabi, and COMPARE Registry Committee. “PATIENT SATISFACTION WITH OBSERVATION OR HORMONAL THERAPY AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) AFTER BIOCHEMICAL FAILURE IN MEN WITH PROSTATE CANCER: RESULTS FROM THE COMPARE REGISTRY.” Journal of Urology 181, no. 4S (April 2009): 90–90. https://doi.org/10.1016/s0022-5347(09)60255-x.
    Full Text
  - Cole, Bernard F., Richard F. Logan, Susan Halabi, Robert Benamouzig, Robert S. Sandler, Matthew J. Grainge, Stanislas Chaussade, and John A. Baron. “Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.” J Natl Cancer Inst 101, no. 4 (February 18, 2009): 256–66. https://doi.org/10.1093/jnci/djn485.
    Full Text Link to Item
  - Armstrong, A. J., S. Halabi, R. de Wit, I. F. Tannock, and M. Eisenberger. “The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.” Prostate Cancer Prostatic Dis 12, no. 1 (2009): 88–93. https://doi.org/10.1038/pcan.2008.36.
    Full Text Link to Item
  - Kelly, William Kevin, Susan Halabi, Aymen Elfiky, San-San Ou, Jeff Bogart, Michael Zelefsky, Eric Small, and Eric Cancer Leukemia Group B. “Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.” Cancer 113, no. 11 (December 1, 2008): 3137–45. https://doi.org/10.1002/cncr.23910.
    Full Text Link to Item
  - Kim, Sangmi, Christopher Martin, Joseph Galanko, John T. Woosley, Jane C. Schroeder, Temitope O. Keku, Jessie A. Satia, Susan Halabi, and Robert S. Sandler. “Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans.” Am J Epidemiol 168, no. 11 (December 1, 2008): 1292–1300. https://doi.org/10.1093/aje/kwn255.
    Full Text Link to Item
  - Rini, Brian I., Susan Halabi, Jonathan E. Rosenberg, Walter M. Stadler, Daniel A. Vaena, San-San Ou, Laura Archer, et al. “Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.” J Clin Oncol 26, no. 33 (November 20, 2008): 5422–28. https://doi.org/10.1200/JCO.2008.16.9847.
    Full Text Link to Item
  - Hurwitz, Mark D., Susan Halabi, San-San Ou, Lamar S. McGinnis, Michael R. Keuttel, Steven J. Dibiase, and Eric J. Small. “Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.” Int J Radiat Oncol Biol Phys 72, no. 3 (November 1, 2008): 814–19. https://doi.org/10.1016/j.ijrobp.2008.01.010.
    Full Text Link to Item
  - Potthoff, Richard F., Susan Halabi, Joellen M. Schildkraut, and Beth Newman. “Flexible Frames and Control Sampling in Case-Control Studies: Weighters (Survey Statisticians) Versus Anti-Weighters (Epidemiologists).” Am Stat 62, no. 4 (November 1, 2008): 307–13. https://doi.org/10.1198/000313008X364525.
    Full Text Link to Item
  - Halabi, S., N. J. Vogelzang, A. B. Kornblith, S. S. Ou, P. W. Kantoff, N. A. Dawson, and E. J. Small. “In reply.” Journal of Clinical Oncology 26, no. 25 (September 18, 2008): 4216–17. https://doi.org/10.1200/JCO.2008.18.5496.
    Full Text
  - Scher, H. I., S. Halabi, I. F. Tannock, M. Morris, C. N. Sternberg, M. A. Carducci, M. A. Eisenberger, et al. “In reply.” Journal of Clinical Oncology 26, no. 21 (September 15, 2008): 3648–49. https://doi.org/10.1200/JCO.2008.17.2494.
    Full Text
  - Dawson, Nancy A., Susan Halabi, San-San Ou, David D. Biggs, Anne Kessinger, Nicholas Vogelzang, Gerald H. Clamon, et al. “A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.” Clin Genitourin Cancer 6, no. 2 (September 2008): 110–16. https://doi.org/10.3816/CGC.2008.n.017.
    Full Text Link to Item
  - Armstrong, A. J., S. Halabi, I. F. Tannock, D. Ronald, and M. A. Eisenberger. “The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 5074–5074. https://doi.org/10.1200/jco.2008.26.15_suppl.5074.
    Full Text
  - Halabi, Susan, Nicholas J. Vogelzang, Alice B. Kornblith, San-San Ou, Philip W. Kantoff, Nancy A. Dawson, and Eric J. Small. “Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.” J Clin Oncol 26, no. 15 (May 20, 2008): 2544–49. https://doi.org/10.1200/JCO.2007.15.0367.
    Full Text Link to Item
  - Shapiro, C. L., S. Halabi, G. Gibson, D. J. Weckstein, J. Kirshner, W. M. Sikov, E. P. Winer, et al. “Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980.” Journal of Clinical Oncology 26, no. 15 (May 20, 2008).
    Link to Item
  - D’Amico, Anthony V., Susan Halabi, Clare Tempany, David Titelbaum, George K. Philips, Marian Loffredo, Elizabeth McMahon, et al. “Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study.” Int J Radiat Oncol Biol Phys 71, no. 1 (May 1, 2008): 9–15. https://doi.org/10.1016/j.ijrobp.2007.09.033.
    Full Text Link to Item
  - D’Amico, Anthony V., Susan Halabi, Robin Vollmer, Marian Loffredo, Elizabeth McMahon, Ben Sanford, Laura Archer, et al. “p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).” Urology 71, no. 5 (May 2008): 933–37. https://doi.org/10.1016/j.urology.2007.11.005.
    Full Text Link to Item
  - Halabi, Susan. “Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer.” Urol Oncol 26, no. 3 (May 2008): 300–307. https://doi.org/10.1016/j.urolonc.2006.11.007.
    Full Text Link to Item
  - Moorman, Patricia G., Brian Calingaert, Rachel T. Palmieri, Edwin S. Iversen, Rex C. Bentley, Susan Halabi, Andrew Berchuck, and Joellen M. Schildkraut. “Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women.” Am J Epidemiol 167, no. 9 (May 1, 2008): 1059–69. https://doi.org/10.1093/aje/kwn006.
    Full Text Link to Item
  - Rosenberg, J. E., S. Halabi, B. L. Sanford, A. L. Himelstein, J. N. Atkins, R. J. Hohl, F. Millard, D. F. Bajorin, E. J. Small, and E. J. Cancer and Leukemia Group B. “Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.” Ann Oncol 19, no. 5 (May 2008): 946–50. https://doi.org/10.1093/annonc/mdm600.
    Full Text Link to Item
  - Singh, B., S. Halabi, and M. J. Schell. “Sample size selection in clinical trials when population means are subject to a partial order: One-sided ordered alternatives.” Journal of Applied Statistics 35, no. 5 (May 1, 2008): 583–600. https://doi.org/10.1080/02664760801924780.
    Full Text
  - Scher, Howard I., Susan Halabi, Ian Tannock, Michael Morris, Cora N. Sternberg, Michael A. Carducci, Mario A. Eisenberger, et al. “Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.” J Clin Oncol 26, no. 7 (March 1, 2008): 1148–59. https://doi.org/10.1200/JCO.2007.12.4487.
    Full Text Link to Item
  - Schildkraut, Joellen M., Patricia G. Moorman, Amy E. Bland, Susan Halabi, Brian Calingaert, Regina Whitaker, Paula S. Lee, et al. “Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup.” Cancer Epidemiol Biomarkers Prev 17, no. 3 (March 2008): 585–93. https://doi.org/10.1158/1055-9965.EPI-07-0596.
    Full Text Link to Item
  - Garmey, Edward G., Oliver Sartor, Susan Halabi, and Nicholas J. Vogelzang. “Second-line chemotherapy for advanced hormone-refractory prostate cancer.” Clin Adv Hematol Oncol 6, no. 2 (February 2008): 118–32.
    Link to Item
  - Kim, Sangmi, Temitope O. Keku, Christopher Martin, Joseph Galanko, John T. Woosley, Jane C. Schroeder, Jessie A. Satia, Susan Halabi, and Robert S. Sandler. “Circulating levels of inflammatory cytokines and risk of colorectal adenomas.” Cancer Res 68, no. 1 (January 1, 2008): 323–28. https://doi.org/10.1158/0008-5472.CAN-07-2924.
    Full Text Link to Item
  - Philips, George K., Susan Halabi, Ben L. Sanford, Dean Bajorin, Eric J. Small, and Eric J. Cancer and Leukaemia Group B. “A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102.” Bju Int 101, no. 1 (January 2008): 20–25. https://doi.org/10.1111/j.1464-410X.2007.07226.x.
    Full Text Link to Item
  - Potthoff, Richard F., Susan Halabi, Joellen M. Schildkraut, and Beth Newman. “Flexible Frames and Control Sampling in Case-Control Studies.” The American Statistician 62, no. 4 (2008): 307–13.
  - Halabi, Susan, San-San Ou, Nicholas J. Vogelzang, and Eric J. Small. “Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.” Cancer 110, no. 7 (October 1, 2007): 1478–84. https://doi.org/10.1002/cncr.22932.
    Full Text Link to Item
  - “ASCO 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma: Guideline Summary.” J Oncol Pract 3, no. 4 (July 2007): 236. https://doi.org/10.1200/JOP.0748502.
    Full Text Link to Item
  - Kyle, Robert A., Gary C. Yee, Mark R. Somerfield, Patrick J. Flynn, Susan Halabi, Sundar Jagannath, Robert Z. Orlowski, et al. “American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.” J Clin Oncol 25, no. 17 (June 10, 2007): 2464–72. https://doi.org/10.1200/JCO.2007.12.1269.
    Full Text Link to Item
  - Ryan, Charles J., Susan Halabi, San-San Ou, Nicholas J. Vogelzang, Philip Kantoff, and Eric J. Small. “Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.” Clin Cancer Res 13, no. 7 (April 1, 2007): 2030–37. https://doi.org/10.1158/1078-0432.CCR-06-2344.
    Full Text Link to Item
  - Schildkraut, Joellen M., Susan K. Murphy, Rachel T. Palmieri, Edwin Iversen, Patricia G. Moorman, Zhiqing Huang, Susan Halabi, et al. “Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer.” Cancer Epidemiol Biomarkers Prev 16, no. 3 (March 2007): 473–80. https://doi.org/10.1158/1055-9965.EPI-06-0868.
    Full Text Link to Item
  - Halabi, Susan, Nicholas J. Vogelzang, San-San Ou, and Eric J. Small. “The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.” J Urol 177, no. 2 (February 2007): 531–34. https://doi.org/10.1016/j.juro.2006.09.050.
    Full Text Link to Item
  - Stadler, Walter M., Susan Halabi, Brian Rini, Marc S. Ernstoff, Enrique Davila, Joel Picus, Robert Barrier, Eric J. Small, and Eric J. Cancer and Leukemia Group B. “A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.” Cancer 107, no. 6 (September 15, 2006): 1273–79. https://doi.org/10.1002/cncr.22117.
    Full Text Link to Item
  - Halabi, Susan, Nicholas J. Vogelzang, San-San Ou, Wm Kevin Kelly, and Eric J. Small. “Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies.” J Urol 176, no. 1 (July 2006): 81–86. https://doi.org/10.1016/S0022-5347(06)00566-0.
    Full Text Link to Item
  - Rini, Brian I., Susan Halabi, Robert Barrier, Kim A. Margolin, David Avigan, Theodore Logan, Walter M. Stadler, et al. “Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.” Biol Blood Marrow Transplant 12, no. 7 (July 2006): 778–85. https://doi.org/10.1016/j.bbmt.2006.03.011.
    Full Text Link to Item
  - Halabi, S., S. Ou, N. J. Vogelzang, and E. J. Small. “An elevated body mass (BMI) index predicts for better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC).” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 4556.
    Link to Item
  - Philips, G., B. Sanford, S. Halabi, D. Bajorin, and E. J. Small. “Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 4578.
    Link to Item
  - Picus, J., S. Halabi, E. Small, A. Hussain, G. Philips, E. Kaplan, and N. Vogelzang. “Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 4573.
    Link to Item
  - Rosenberg, J. E., S. Halabi, B. L. Sanford, A. L. Himelstein, J. N. Atkins, R. Hohl, S. L. Seagren, D. F. Bajorin, and E. J. Small. “CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC).” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 4582.
    Link to Item
  - Sartor, O., C. L. Bennett, S. Halabi, M. Kattan, and P. Scardino. “Race/ethnicity, literacy, and prostate cancer: Initial findings from the COMPARE registry.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 4620.
    Link to Item
  - Small, Eric J., Susan Halabi, Phillip Kantoff, Anthony D’Amico, Walter Stadler, W Kevin Kelley, James Mohler, Dean Bajorin, and Nicholas J. Vogelzang. “Activities and accomplishments of the cancer and leukemia group B genitourinary committee.” Clin Cancer Res 12, no. 11 Pt 2 (June 1, 2006): 3596s-3600s. https://doi.org/10.1158/1078-0432.CCR-06-9005.
    Full Text Link to Item
  - Humphrey, Peter A., Susan Halabi, Joel Picus, Ben Sanford, Nicholas J. Vogelzang, Eric J. Small, and Philip W. Kantoff. “Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.” Clin Genitourin Cancer 4, no. 4 (March 2006): 269–74. https://doi.org/10.3816/CGC.2006.n.006.
    Full Text Link to Item
  - Schildkraut, Joellen M., Patricia G. Moorman, Susan Halabi, Brian Calingaert, Jeffrey R. Marks, and Andrew Berchuck. “Analgesic drug use and risk of ovarian cancer.” Epidemiology 17, no. 1 (January 2006): 104–7. https://doi.org/10.1097/01.ede.0000190538.55645.f8.
    Full Text Link to Item
  - Rich, Jeremy N., Sith Sathornsumetee, Stephen T. Keir, Mark W. Kieran, Andrea Laforme, Arja Kaipainen, Roger E. McLendon, et al. “ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.” Clin Cancer Res 11, no. 22 (November 15, 2005): 8145–57. https://doi.org/10.1158/1078-0432.CCR-05-0319.
    Full Text Link to Item
  - Ross, Robert W., Susan Halabi, San-San Ou, Barur R. Rajeshkumar, Bruce A. Woda, Nicholas J. Vogelzang, Eric J. Small, Mary-Ellen Taplin, Philip W. Kantoff, and Philip W. Cancer and Leukemia Group B. “Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study.” Clin Cancer Res 11, no. 22 (November 15, 2005): 8109–13. https://doi.org/10.1158/1078-0432.CCR-05-1250.
    Full Text Link to Item
  - Hoyo, Cathrine, Andrew Berchuck, Susan Halabi, Rex C. Bentley, Patricia Moorman, Brian Calingaert, and Joellen M. Schildkraut. “Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women.” Cancer Causes Control 16, no. 8 (October 2005): 955–63. https://doi.org/10.1007/s10552-005-3205-y.
    Full Text Link to Item
  - Taplin, Mary-Ellen, Daniel J. George, Susan Halabi, Ben Sanford, Philip G. Febbo, Kristen T. Hennessy, Christos G. Mihos, Nicholas J. Vogelzang, Eric J. Small, and Philip W. Kantoff. “Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.” Urology 66, no. 2 (August 2005): 386–91. https://doi.org/10.1016/j.urology.2005.03.040.
    Full Text Link to Item
  - Moorman, Patricia G., Joellen M. Schildkraut, Brian Calingaert, Susan Halabi, and Andrew Berchuck. “Menopausal hormones and risk of ovarian cancer.” Am J Obstet Gynecol 193, no. 1 (July 2005): 76–82. https://doi.org/10.1016/j.ajog.2004.11.013.
    Full Text Link to Item
  - Moorman, P. G., A. Berchuck, B. Calingaert, S. Halabi, and A. M. Schildkraut. “Antidepressant medication use for and risk of ovarian cancer (vol 105, pg 725, 2005).” Obstetrics and Gynecology 105, no. 6 (June 2005): 1495–1495.
    Link to Item
  - Spillman, Monique A., Joellen M. Schildkraut, Susan Halabi, Patricia Moorman, Brian Calingaert, Rex C. Bentley, Jeffrey R. Marks, Susan Murphy, and Andrew Berchuck. “Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk.” Gynecol Oncol 97, no. 2 (May 2005): 543–49. https://doi.org/10.1016/j.ygyno.2005.01.025.
    Full Text Link to Item
  - Halabi, Susan, Eric J. Small, and Nicholas J. Vogelzang. “Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.” J Clin Oncol 23, no. 10 (April 1, 2005): 2434–35. https://doi.org/10.1200/JCO.2005.05.890.
    Full Text Link to Item
  - Moorman, Patricia G., Andrew Berchuck, Brian Calingaert, Susan Halabi, and Joellen M. Schildkraut. “Antidepressant medication use [corrected] and risk of ovarian cancer.” Obstet Gynecol 105, no. 4 (April 2005): 725–30. https://doi.org/10.1097/01.AOG.0000157113.98061.eb.
    Full Text Link to Item
  - George, Daniel J., Susan Halabi, Timothy F. Shepard, Ben Sanford, Nicholas J. Vogelzang, Eric J. Small, and Philip W. Kantoff. “The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.” Clin Cancer Res 11, no. 5 (March 1, 2005): 1815–20. https://doi.org/10.1158/1078-0432.CCR-04-1560.
    Full Text Link to Item
  - Vanbeek, Marta J., John S. Strauss, and Ingrid Nygaard. “Flushing and papules in a middle-aged woman.” Obstet Gynecol 105, no. 2 (February 2005): 397–401. https://doi.org/10.1097/01.AOG.0000151956.00804.78.
    Full Text Link to Item
  - Berchuck, Andrew, Joellen M. Schildkraut, Robert M. Wenham, Brian Calingaert, Shazia Ali, Amy Henriott, Susan Halabi, et al. “Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.” Cancer Epidemiol Biomarkers Prev 13, no. 12 (December 2004): 2141–47.
    Link to Item
  - Amin, Asim, Susan Halabi, Edward P. Gelmann, Walter Stadler, Nicholas Vogelzang, and Eric Small. “9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.” Urol Oncol 22, no. 5 (September 2004): 398–403. https://doi.org/10.1016/j.urolonc.2004.05.002.
    Full Text Link to Item
  - Halabi, Susan, Eric J. Small, Nicholas J. Vogelzang, Robert C. Barrier, Stephen L. George, and Timothy D. Gilligan. “Impact of race on survival in men with metastatic hormone-refractory prostate cancer.” Urology 64, no. 2 (August 2004): 212–17. https://doi.org/10.1016/j.urology.2004.04.014.
    Full Text Link to Item
  - Burns, C Patrick, Susan Halabi, Gerald Clamon, Ellen Kaplan, Raymond J. Hohl, James N. Atkins, Michael A. Schwartz, Brett A. Wagner, and Electra Paskett. “Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia.” Cancer 101, no. 2 (July 15, 2004): 370–78. https://doi.org/10.1002/cncr.20362.
    Full Text Link to Item
  - D’Amico, A. V., S. Halabi, N. J. Vogelzang, and E. J. Small. “A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 4506.
    Link to Item
  - Halabi, S., E. J. Small, T. Gilligian, R. Barrier, S. George, and N. J. Vogelzang. “The effect of race on progression-free survival in patients with metastatic hormone-refractory prostate cancer (HRPC): a pooled analysis of CALGB studies.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 4573.
    Link to Item
  - Humphrey, P., S. Halabi, J. Picus, N. Vogelzang, E. Small, P. Kantoff, and P. Cancer and Leukemia Group B (CALGB). “Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 9613.
    Link to Item
  - Philips, G., S. Halabi, B. Sanford, D. Bajorin, and E. Small. “Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 4540.
    Link to Item
  - Picus, J., S. Halabi, E. Small, A. Hussain, G. Philips, E. Kaplan, and N. Vogelzang. “Efficacy of peripheral androgen blockade on prostate cancer: Results of CALGB 9782.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 4559.
    Link to Item
  - Ryan, C. J., S. Halabi, E. Kaplan, N. Vogelzang, P. Kantoff, and E. J. Small. “Use of adrenal androgen levels to predict response to ketoconazole in patients with androgen independent prostate cancer: Results from CALGB 9583.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 4558.
    Link to Item
  - Stadler, W. M., S. Halabi, M. S. Ernstoff, R. Barrier, E. Davila, J. Picus, and E. J. Small. “A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 4515.
    Link to Item
  - Taplin, M. E., D. J. George, S. Halabi, W. R. Sellers, B. Sanford, K. T. Hennessy, C. G. Mihos, E. J. Small, and P. W. Kantoff. “Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 4557.
    Link to Item
  - Halabi, Susan, and Bahadur Singh. “Sample size determination for comparing several survival curves with unequal allocations.” Stat Med 23, no. 11 (June 15, 2004): 1793–1815. https://doi.org/10.1002/sim.1771.
    Full Text Link to Item
  - Rini, Brian I., Susan Halabi, John Taylor, Eric J. Small, Richard L. Schilsky, and Richard L. Cancer and Leukemia Group B. “Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.” Clin Cancer Res 10, no. 8 (April 15, 2004): 2584–86. https://doi.org/10.1158/1078-0432.ccr-03-0605.
    Full Text Link to Item
  - Small, Eric J., Susan Halabi, Nancy A. Dawson, Walter M. Stadler, Brian I. Rini, Joel Picus, Preston Gable, Frank M. Torti, Ellen Kaplan, and Nicholas J. Vogelzang. “Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).” J Clin Oncol 22, no. 6 (March 15, 2004): 1025–33. https://doi.org/10.1200/JCO.2004.06.037.
    Full Text Link to Item
  - Scher, Howard I., Mario Eisenberger, Anthony V. D’Amico, Susan Halabi, Eric J. Small, Michael Morris, Michael W. Kattan, et al. “Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.” J Clin Oncol 22, no. 3 (February 1, 2004): 537–56. https://doi.org/10.1200/JCO.2004.07.099.
    Full Text Link to Item
  - Oh, William K., Susan Halabi, W Kevin Kelly, Cary Werner, Paul A. Godley, Nicholas J. Vogelzang, Eric J. Small, and Eric J. Cancer and Leukemia Group B 99813. “A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.” Cancer 98, no. 12 (December 15, 2003): 2592–98. https://doi.org/10.1002/cncr.11829.
    Full Text Link to Item
  - Sandler, R. S., S. Halabi, and J. A. Baron. “Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer.” Evidence Based Medicine 8, no. 6 (November 1, 2003): 179. https://doi.org/10.1136/ebm.8.6.179.
    Full Text
  - Taplin, Mary-Ellen, Barur Rajeshkumar, Susan Halabi, Cary P. Werner, Bruce A. Woda, Joel Picus, Walter Stadler, et al. “Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.” J Clin Oncol 21, no. 14 (July 15, 2003): 2673–78. https://doi.org/10.1200/JCO.2003.11.102.
    Full Text Link to Item
  - Halabi, Susan, Chuan-Chuan Wun, and Barry R. Davis. “Analysis of survival data with missing measurements of a time-dependent binary covariate.” J Biopharm Stat 13, no. 2 (May 2003): 253–70. https://doi.org/10.1081/BIP-120019270.
    Full Text Link to Item
  - Small, Eric J., Susan Halabi, Guido Dalbagni, Raj Pruthi, George Phillips, Martin Edelman, Dean Bajorin, and Dean Cancer and Leukemia Group B. “Overview of bladder cancer trials in the Cancer and Leukemia Group B.” Cancer 97, no. 8 Suppl (April 15, 2003): 2090–98. https://doi.org/10.1002/cncr.11299.
    Full Text Link to Item
  - Halabi, Susan, Eric J. Small, Philip W. Kantoff, Michael W. Kattan, Ellen B. Kaplan, Nancy A. Dawson, Ellis G. Levine, Brent A. Blumenstein, and Nicholas J. Vogelzang. “Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.” J Clin Oncol 21, no. 7 (April 1, 2003): 1232–37. https://doi.org/10.1200/JCO.2003.06.100.
    Full Text Link to Item
  - Sandler, Robert S., Susan Halabi, John A. Baron, Susan Budinger, Electra Paskett, Roger Keresztes, Nicholas Petrelli, et al. “A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.” N Engl J Med 348, no. 10 (March 6, 2003): 883–90. https://doi.org/10.1056/NEJMoa021633.
    Full Text Link to Item
  - Lancaster, Johnathan M., Robert M. Wenham, Susan Halabi, Brian Calingaert, Jeffrey R. Marks, Patricia G. Moorman, Rex C. Bentley, Andrew Berchuck, and Joellen M. Schildkraut. “No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.” Cancer Epidemiol Biomarkers Prev 12, no. 3 (March 2003): 226–27.
    Link to Item
  - Halabi, Susan, Eric J. Small, Daniel F. Hayes, Nicholas J. Vogelzang, and Philip W. Kantoff. “Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583.” J Clin Oncol 21, no. 3 (February 1, 2003): 490–95. https://doi.org/10.1200/JCO.2003.04.104.
    Full Text Link to Item
  - Sandler, R. S., S. Halabi, J. A. Baron, S. Budinger, E. Paskett, R. Keresztes, N. Petrelli, et al. “A randomized trial of aspirin to prevent colorectal adenomas in patients with previous.” European Journal of Gastroenterology and Hepatology 15, no. 5 (January 1, 2003): 579–80. https://doi.org/10.1097/00042737-200305000-00032.
    Full Text
  - Moorman, Patricia G., Joellen M. Schildkraut, Brian Calingaert, Susan Halabi, Marilyn F. Vine, and Andrew Berchuck. “Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States).” Cancer Causes Control 13, no. 9 (November 2002): 807–11. https://doi.org/10.1023/a:1020678100977.
    Full Text Link to Item
  - Small, Eric J., Susan Halabi, Mark J. Ratain, Gary Rosner, Walter Stadler, David Palchak, Ernest Marshall, et al. “Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.” J Clin Oncol 20, no. 16 (August 15, 2002): 3369–75. https://doi.org/10.1200/JCO.2002.10.022.
    Full Text Link to Item
  - McBride, Colleen M., Lori A. Bastian, Susan Halabi, Laura Fish, Isaac M. Lipkus, Hayden B. Bosworth, Barbara K. Rimer, and Ilene C. Siegler. “A tailored intervention to aid decision-making about hormone replacement therapy.” Am J Public Health 92, no. 7 (July 2002): 1112–14. https://doi.org/10.2105/ajph.92.7.1112.
    Full Text Link to Item
  - Rimer, Barbara K., Susan Halabi, Celette Sugg Skinner, Isaac M. Lipkus, Tara S. Strigo, Ellen B. Kaplan, and Gregory P. Samsa. “Effects of a mammography decision-making intervention at 12 and 24 months.” Am J Prev Med 22, no. 4 (May 2002): 247–57. https://doi.org/10.1016/s0749-3797(02)00417-8.
    Full Text Link to Item
  - Levine, Ellis G., Susan Halabi, John D. Roberts, Ellen B. Kaplan, Randall Rago, James N. Atkins, and Nicholas J. Vogelzang. “Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.” Cancer 94, no. 3 (February 1, 2002): 665–72. https://doi.org/10.1002/cncr.10217.
    Full Text Link to Item
  - Halabi, S., M. R. Conaway, E. J. Small, N. J. Vogelzang, and N. A. Dawson. “Serum prostate specific antigen as a predictor of survival in prostate cancer patients treated with second-line hormonal therapy (CALGB 9181).” Prostate Journal 3, no. 1 (September 27, 2001): 18–25. https://doi.org/10.1046/j.1525-1411.2001.31003.x.
    Full Text
  - Bastian, L. A., I. M. Lipkus, M. N. Kuchibhatla, H. H. Weng, S. Halabi, P. D. Ryan, C. S. Skinner, and B. K. Rimer. “Women's interest in chemoprevention for breast cancer.” Arch Intern Med 161, no. 13 (July 9, 2001): 1639–44. https://doi.org/10.1001/archinte.161.13.1639.
    Full Text Link to Item
  - George, D. J., S. Halabi, T. F. Shepard, N. J. Vogelzang, D. F. Hayes, E. J. Small, P. W. Kantoff, and P. W. Cancer and Leukemia Group B 9480. “Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.” Clin Cancer Res 7, no. 7 (July 2001): 1932–36.
    Link to Item
  - Schildkraut, J. M., G. S. Cooper, S. Halabi, B. Calingaert, P. Hartge, and A. S. Whittemore. “Age at natural menopause and the risk of epithelial ovarian cancer.” Obstet Gynecol 98, no. 1 (July 2001): 85–90. https://doi.org/10.1016/s0029-7844(01)01388-6.
    Full Text Link to Item
  - Kantoff, P. W., S. Halabi, D. A. Farmer, D. F. Hayes, N. A. Vogelzang, and E. J. Small. “Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.” J Clin Oncol 19, no. 12 (June 15, 2001): 3025–28. https://doi.org/10.1200/JCO.2001.19.12.3025.
    Full Text Link to Item
  - Halabi, S., J. M. Schildkraut, G. S. Cooper, B. Calingaert, P. Hartge, and A. S. Whittemore. “Age at natural menopause and the risk of developing invasive epithelial ovarian cancer.” American Journal of Epidemiology 153, no. 11 (June 1, 2001): S111–S111.
    Link to Item
  - Moorman, P. G., B. Calingaert, M. Vine, S. Halabi, A. Berchuck, and J. M. Schildkraut. “Comparison of two methods for calculating lifetime ovulatory cycles.” American Journal of Epidemiology 153, no. 11 (June 1, 2001): S138–S138.
    Link to Item
  - Rimer, B. K., S. Halabi, C. Sugg Skinner, E. B. Kaplan, Y. Crawford, G. P. Samsa, T. S. Strigo, and I. M. Lipkus. “The short-term impact of tailored mammography decision-making interventions.” Patient Educ Couns 43, no. 3 (June 2001): 269–85. https://doi.org/10.1016/s0738-3991(00)00172-5.
    Full Text Link to Item
  - Savarese, D. M., S. Halabi, V. Hars, W. L. Akerley, M. E. Taplin, P. A. Godley, A. Hussain, E. J. Small, and N. J. Vogelzang. “Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.” J Clin Oncol 19, no. 9 (May 1, 2001): 2509–16. https://doi.org/10.1200/JCO.2001.19.9.2509.
    Full Text Link to Item
  - Bok, R. A., S. Halabi, D. T. Fei, C. R. Rodriquez, D. F. Hayes, N. J. Vogelzang, P. Kantoff, M. A. Shuman, and E. J. Small. “Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.” Cancer Res 61, no. 6 (March 15, 2001): 2533–36.
    Link to Item
  - Sandler, R. S., S. Halabi, E. B. Kaplan, J. A. Baron, E. Paskett, and N. J. Petrelli. “Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial.” Cancer 91, no. 5 (March 1, 2001): 1040–45.
    Link to Item
  - Suba, E. J., C. H. Nguyen, B. D. Nguyen, S. S. Raab, and S. S. Viet/American Cervical Cancer Prevention Project. “De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.” Cancer 91, no. 5 (March 1, 2001): 928–39.
    Link to Item
  - Halabi, S., C. S. Skinner, G. P. Samsa, T. S. Strigo, Y. S. Crawford, and B. K. Rimer. “Factors associated with repeat mammography screening.” J Fam Pract 49, no. 12 (December 2000): 1104–12.
    Link to Item
  - Lipkus, I. M., M. Kuchibhatla, C. M. McBride, H. B. Bosworth, K. I. Pollak, I. C. Siegler, and B. K. Rimer. “Relationships among breast cancer perceived absolute risk, comparative risk, and worries.” Cancer Epidemiol Biomarkers Prev 9, no. 9 (September 2000): 973–75.
    Link to Item
  - Lipkus, I. M., S. Halabi, T. S. Strigo, and B. K. Rimer. “The impact of abnormal mammograms on psychosocial outcomes and subsequent screening.” Psychooncology 9, no. 5 (September 2000): 402–10. https://doi.org/10.1002/1099-1611(200009/10)9:5<402::aid-pon475>3.0.co;2-u.
    Full Text Link to Item
  - Alpers, L., K. Chrouser, S. Halabi, T. Moeti, A. Reingold, N. Binkin, and T. Kenyon. “Validation of the surveillance system for tuberculosis in Botswana.” Int J Tuberc Lung Dis 4, no. 8 (August 2000): 737–43.
    Link to Item
  - McBride, C. M., S. Halabi, G. Bepler, P. Lyna, L. McIntyre, I. Lipkus, J. Albright, and K. O’Briant. “Maximizing the motivational impact of feedback of lung cancer susceptibility on smokers' desire to quit.” J Health Commun 5, no. 3 (July 2000): 229–41. https://doi.org/10.1080/10810730050131406.
    Full Text Link to Item
  - Dawson, N. A., M. Conaway, S. Halabi, E. P. Winer, E. J. Small, D. Lake, and N. J. Vogelzang. “A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.” Cancer 88, no. 4 (February 15, 2000): 825–34.
    Link to Item
  - Demark-Wahnefried, W., S. Halabi, V. Hars, E. Winer, P. K. Marcom, K. Blackwell, L. Harris, and B. K. Rimer. “Increased weight & body fatness associated with chemotherapy for breast cancer ... & what can be done?” Cancer Epidemiology Biomarkers & Prevention 9, no. 2 (February 1, 2000): 236–236.
    Link to Item
  - Lipkus, I. M., B. K. Rimer, S. Halabi, and T. S. Strigo. “Can tailored interventions increase mammography use among HMO women?” Am J Prev Med 18, no. 1 (January 2000): 1–10. https://doi.org/10.1016/s0749-3797(99)00106-3.
    Full Text Link to Item
  - Schildkraut, J. M., S. Halabi, E. Bastos, P. A. Marchbanks, J. A. McDonald, and A. Berchuck. “Prognostic factors in early-onset epithelial ovarian cancer: a population-based study.” Obstet Gynecol 95, no. 1 (January 2000): 119–27. https://doi.org/10.1016/s0029-7844(99)00535-9.
    Full Text Link to Item
  - Burns, C. P., S. Halabi, G. H. Clamon, V. Hars, B. A. Wagner, R. J. Hohl, E. Lester, J. J. Kirshner, V. Vinciguerra, and E. Paskett. “Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473.” Clin Cancer Res 5, no. 12 (December 1999): 3942–47.
    Link to Item
  - Savarese, D., M. E. Taplin, S. Halabi, V. Hars, W. Kreis, and N. Vogelzang. “A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780.” Seminars in Oncology 26, no. 5 SUPPL. 17 (December 1, 1999): 39–44.
  - Bastian, L. A., C. M. McBride, S. Halabi, L. J. Fish, C. S. Skinner, E. B. Kaplan, H. B. Bosworth, B. K. Rimer, and I. C. Siegler. “Attitudes and Knowledge Associated with being Undecided about Hormone Replacement Therapy: Results from a Community Sample.” Women’S Health Issues 9, no. 6 (November 1999): 330–37. https://doi.org/10.1016/s1049-3867(99)90001-4.
    Full Text
  - Bubley, G. J., M. Carducci, W. Dahut, N. Dawson, D. Daliani, M. Eisenberger, W. D. Figg, et al. “Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.” J Clin Oncol 17, no. 11 (November 1999): 3461–67. https://doi.org/10.1200/JCO.1999.17.11.3461.
    Full Text Link to Item
  - Savarese, D., M. E. Taplin, S. Halabi, V. Hars, W. Kreis, and N. Vogelzang. “A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.” Semin Oncol 26, no. 5 Suppl 17 (October 1999): 39–44.
    Link to Item
  - Savarese, D., M. E. Taplin, S. Halabi, V. Hars, W. Kreis, and N. Vogelzang. “A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780.” Seminars in Oncology 26, no. 5 (October 1, 1999): 39–44.
    Link to Item
  - Kantoff, P. W., S. Halabi, M. Conaway, J. Picus, J. Kirshner, V. Hars, D. Trump, E. P. Winer, and N. J. Vogelzang. “Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.” J Clin Oncol 17, no. 8 (August 1999): 2506–13. https://doi.org/10.1200/JCO.1999.17.8.2506.
    Full Text Link to Item
  - Rimer, B. K., S. Halabi, T. S. Strigo, Y. Crawford, and I. M. Lipkus. “Confusion about mammography: prevalence and consequences.” J Womens Health Gend Based Med 8, no. 4 (May 1999): 509–20. https://doi.org/10.1089/jwh.1.1999.8.509.
    Full Text Link to Item
  - Anreder, M. B., S. M. Freeman, A. Merogi, S. Halabi, and A. J. Marrogi. “p53, c-erbB2, and PCNA status in benign, proliferative and malignant ovarian surface epithelial neoplasms: a study of 75 cases.” Arch Pathol Lab Med 123, no. 4 (April 1999): 310–16. https://doi.org/10.1043/0003-9985(1999)123<0310:PCEAPS>2.0.CO;2.
    Full Text Link to Item
  - E S Johnson S Halabi G Netto G Lucier W Bechtold R Henderson, DONALD E. “Detection of low level benzene exposure in supermarket wrappers by urinary muconic acid.” Biomarkers 4, no. 2 (1999): 106–17. https://doi.org/10.1080/135475099230912.
    Full Text Link to Item
  - Demark-Wahnefried, W., S. Halabi, and D. F. Paulson. “Serum androgens: associations with prostate cancer risk and hair patterning.” J Androl 19, no. 5 (September 1998): 631.
    Link to Item
  - Demark-Wahnefried, W., S. Halabi, and D. F. Paulson. “Untitled.” Journal of Andrology 19, no. 5 (September 1, 1998): 631–631.
    Link to Item
  - Coughlin, S. S., S. Halabi, and C. Metayer. “Barriers to cardiac transplantation in idiopathic dilated cardiomyopathy: the Washington, DC, Dilated Cardiomyopathy Study.” J Natl Med Assoc 90, no. 6 (June 1998): 342–48.
    Link to Item
  - Demark-Wahnefried, W., S. Halabi, and D. F. Paulson. “Letter to the editor.” Journal of Andrology 19, no. 5 (January 1, 1998): 631.
  - Schildkraut, J. M., E. Bastos, S. Halabi, and A. Berchuck. “Response.” Jnci Journal of the National Cancer Institute 89, no. 22 (November 19, 1997): 1727–1727. https://doi.org/10.1093/jnci/89.22.1727.
    Full Text
  - Wodnicki, P., S. Lockett, M. Rhadhakrishna Pillai, S. Halabi, A. McKalip, and B. Herman. “Automated image microscopy.” Chemical Analysis 137 (December 1, 1996): 31–54.
  - Coughlin, S. S., S. Halabi, and C. Metayer. “Barriers to cardiac transplantation in idiopathic dilated cardiomyopathy: The Washington, DC dilated cardiomyopathy study.” Circulation 94, no. 8 (October 15, 1996): 4043–4043.
    Link to Item
  - Becher, R., O. Kloke, J. Hayungs, G. Hartwich, H. Bartels, J. Szanto, E. Wolf, et al. “Epirubicin and ifosfamide in metastatic breast cancer.” Seminars in Oncology 23, no. 3 SUPPL. 7 (August 27, 1996): 28–33.
  - Crane, M. M., S. S. Strom, S. Halabi, E. L. Berman, J. J. Fueger, M. R. Spitz, and M. J. Keating. “Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia.” Cancer Epidemiol Biomarkers Prev 5, no. 8 (August 1996): 639–44.
    Link to Item
  - Becher, R., O. Kloke, J. Hayungs, G. Hartwich, H. Bartels, J. Szanto, E. Wolf, et al. “Epirubicin and ifosfamide in metastatic breast cancer.” Semin Oncol 23, no. 3 Suppl 7 (June 1996): 28–33.
    Link to Item
  - Pillai, M. R., S. Halabi, A. McKalip, P. G. Jayaprakash, T. N. Rajalekshmi, M. K. Nair, and B. Herman. “The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.” Cancer Epidemiol Biomarkers Prev 5, no. 5 (May 1996): 329–35.
    Link to Item
  - Munshi, A., O. L. Marrogi, S. Halabi, A. I. Merogi, S. M. Freeman, and A. I. Marrogi. “Oncogene profile in pre versus postmenopausal women with breast carcinoma: Evidence of different p53 mutation patterns.” Faseb Journal 10, no. 6 (April 30, 1996): 839–839.
    Link to Item
  - Ji, W., G. Z. Qu, P. Ye, X. Y. Zhang, S. Halabi, and M. Ehrlich. “Frequent detection of bcl-2/JH translocations in human blood and organ samples by a quantitative polymerase chain reaction assay.” Cancer Res 55, no. 13 (July 1, 1995): 2876–82.
    Link to Item
  - Bondy, M. L., E. D. Lustbader, S. Halabi, E. Ross, and V. G. Vogel. “Validation of a breast cancer risk assessment model in women with a positive family history.” J Natl Cancer Inst 86, no. 8 (April 20, 1994): 620–25. https://doi.org/10.1093/jnci/86.8.620.
    Full Text Link to Item
  - Vernon, S. W., V. G. Vogel, S. Halabi, and M. L. Bondy. “Factors associated with perceived risk of breast cancer among women attending a screening program.” Breast Cancer Res Treat 28, no. 2 (November 1993): 137–44. https://doi.org/10.1007/BF00666426.
    Full Text Link to Item
  - Schusterman, M. A., S. S. Kroll, G. P. Reece, M. J. Miller, N. Ainslie, S. Halabi, and C. M. Balch. “Incidence of autoimmune disease in patients after breast reconstruction with silicone gel implants versus autogenous tissue: a preliminary report.” Ann Plast Surg 31, no. 1 (July 1993): 1–6.
    Link to Item
  - Spitz, M. R., J. J. Fueger, S. Halabi, S. P. Schantz, D. Sample, and T. C. Hsu. “Mutagen sensitivity in upper aerodigestive tract cancer: a case-control analysis.” Cancer Epidemiol Biomarkers Prev 2, no. 4 (July 1993): 329–33.
    Link to Item
  - Peters, G. N., V. G. Vogel, W. P. Evans, M. Bondy, S. Halabi, J. Lord, and E. A. Laville. “The Texas Breast Screening Project: Part I. Mammographic and clinical results.” South Med J 86, no. 4 (April 1993): 385–90. https://doi.org/10.1097/00007611-199304000-00003.
    Full Text Link to Item
  - Vogel, V. G., M. Bondy, S. Halabi, J. Lord, and E. A. Laville. “The Texas Breast Screening Project: Part II. Demographics, risk profiles, and health practices of participants.” South Med J 86, no. 4 (April 1993): 391–96. https://doi.org/10.1097/00007611-199304000-00004.
    Full Text Link to Item
  - Bondy, M. L., M. R. Spitz, S. Halabi, J. J. Fueger, S. P. Schantz, D. Sample, and T. C. Hsu. “Association between family history of cancer and mutagen sensitivity in upper aerodigestive tract cancer patients.” Cancer Epidemiol Biomarkers Prev 2, no. 2 (March 1993): 103–6.
    Link to Item
  - Halabi, S., V. G. Vogel, M. L. Bondy, and S. W. Vernon. “Recruiting older women for screening mammography.” Cancer Detect Prev 17, no. 3 (1993): 359–65.
    Link to Item
  - Bondy, M. L., M. R. Spitz, S. Halabi, J. J. Fueger, and V. G. Vogel. “Low incidence of familial breast cancer among Hispanic women.” Cancer Causes Control 3, no. 4 (July 1992): 377–82. https://doi.org/10.1007/BF00146892.
    Full Text Link to Item
  - Halabi, S., H. Zurayk, R. Awaida, M. Darwish, and B. Saab. “Reliability and validity of self and proxy reporting of morbidity data: a case study from Beirut, Lebanon.” Int J Epidemiol 21, no. 3 (June 1992): 607–12. https://doi.org/10.1093/ije/21.3.607.
    Full Text Link to Item
  - Bondy, M. L., V. G. Vogel, S. Halabi, and E. D. Lustbader. “Identification of women at increased risk for breast cancer in a population-based screening program.” Cancer Epidemiol Biomarkers Prev 1, no. 2 (January 1992): 143–47.
    Link to Item
  - Vernon, S. W., V. G. Vogel, S. Halabi, G. L. Jackson, R. O. Lundy, and G. N. Peters. “Breast cancer screening behaviors and attitudes in three racial/ethnic groups.” Cancer 69, no. 1 (January 1, 1992): 165–74. https://doi.org/10.1002/1097-0142(19920101)69:1<165::aid-cncr2820690128>3.0.co;2-f.
    Full Text Link to Item
  - Armenian, H. K., S. S. Halabi, and M. Khlat. “Epidemiology of primary health problems in Beirut.” J Epidemiol Community Health 43, no. 4 (December 1989): 315–18. https://doi.org/10.1136/jech.43.4.315.
    Full Text Link to Item
  - Armenian, H. K., N. G. Lakkis, A. M. Sibai, and S. S. Halabi. “Hospital visitors as controls.” Am J Epidemiol 127, no. 2 (February 1988): 404–6. https://doi.org/10.1093/oxfordjournals.aje.a114813.
    Full Text Link to Item
  - Zurayk, H., S. Halabi, and M. Deeb. “Measures of social class based on education for use in health studies in developing countries.” J Epidemiol Community Health 41, no. 2 (June 1987): 173–79. https://doi.org/10.1136/jech.41.2.173.
    Full Text Link to Item
  - Khlat, M., S. Halabi, A. Khudr, and V. M. Der Kaloustian. “Perception of consanguineous marriages and their genetic effects among a sample of couples from Beirut.” Am J Med Genet 25, no. 2 (October 1986): 299–306. https://doi.org/10.1002/ajmg.1320250215.
    Full Text Link to Item
  - Khlat, M., and S. Halabi. “Modernization and consanguineous marriage in Beirut.” J Biosoc Sci 18, no. 4 (October 1986): 489–95. https://doi.org/10.1017/s0021932000016503.
    Full Text Link to Item
  - Solomon, Nicole, Yuliya Lokhnygina, and Susan Halabi. “Comparison of regression imputation methods of baseline covariates that predict survival outcomes.” Journal of Clinical and Translational Science, n.d., 1–10. https://doi.org/10.1017/cts.2020.533.
    Full Text
- Book Sections
  - Wu, Yuan, and Susan Halabi. “Interval Censoring.” In Textbook of Clinical Trials in Oncology A Statistical Perspective, edited by Susan Halabi and Stefan Michiels, 493–510. CRC Press, 2019.
  - Wu, Yuan, and Susan Halabi. “Interval Censoring.” In Textbook of Clinical Trials in Oncology A Statistical Perspective, edited by Susan Halabi and Stefan Michiels, 493–510. CRC Press, 2019.
- Conference Papers
  - Armstrong, Andrew J., Jun Luo, Monika Anand, Emmanuel S. Antonarakis, David M. Nanus, Paraskevi Giannakakou, Russell Zelig Szmulewitz, et al. “AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Brown, Landon Carter, Susan Halabi, Joseph Schonhoft, Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Zelig Szmulewitz, et al. “Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, David M. Nanus, Paraskevi Giannakakou, Daniel J. George, Simon Gregory, and Andrew J. Armstrong. “Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Slovin, Susan F., Karen E. Knudsen, Susan Halabi, Mark T. Fleming, Ana M. Molina, Steven Paul Wolf, Renee de Leeuw, et al. “Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Zhang, Tian, Julie Kephart, Elizabeth Bronson, Monika Anand, Christine Daly, Ivan Spasojevic, Hannah Berg, et al. “Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Gupta, Ranju, Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Stacy D. D’Andre, Eyal Meiri, Sagun Shrestha, Sasha L. Warren, Shamika Ranasinghe, and Richard L. Schilsky. “Pertuzumab plus trastuzumab (P plus T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Klute, Kelsey, Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Reza Nazemzadeh, Kathleen J. Yost, Nicole L. Butler, Venu Perla, and Richard L. Schilsky. “Cobimetinib plus vemurafenib (C plus V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Meiri, Eyal, Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Sagun Shrestha, Eugene R. Ahn, Olufunlayo Osayameh, Venu Perla, and Richard L. Schilsky. “Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - George, D. J., M. Casey, E. Degtyarev, MJ Lechuga Frean, P. Aimone, A. Ravaud, S. Halabi, and R. J. Motzer. “Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC).” In Annals of Oncology, Vol. 30. OXFORD UNIV PRESS, 2019.
    Link to Item
  - Alvarez, Ricardo H., Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Tareq Al Baghdadi, Eugene R. Ahn, Seungjean Chai, et al. “Abstract CT146: Sunitinib (S) in patients (Pts) with metastatic colorectal cancer (mCRC) withFLT-3alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” In Clinical Trials. American Association for Cancer Research, 2019. https://doi.org/10.1158/1538-7445.am2019-ct146.
    Full Text
  - Fisher, Julie, Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Ricardo H. Alvarez, Timothy L. Cannon, Pamela Crilley, et al. “Abstract CT135: Cetuximab (C) in patients (Pts) with breast cancer (BC) and non-small cell lung cancer (NSCLC) without reportedKRAS, NRAS, BRAFmutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” In Clinical Trials. American Association for Cancer Research, 2019. https://doi.org/10.1158/1538-7445.am2019-ct135.
    Full Text
  - Alva, Ajjai Shivaram, Pam K. Mangat, Elizabeth Garrett-Mayer, Susan Halabi, Ricardo H. Alvarez, Carmen Julia Calfa, Maged F. Khalil, et al. “Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” In Journal of Clinical Oncology, 37:1014–1014. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.1014.
    Full Text
  - Eastham, James Andrew, Glenn Heller, Susan Halabi, Paul Monk, Steven K. Clinton, Russell Zelig Szmulewitz, Jonathan Coleman, et al. “CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC).” In Journal of Clinical Oncology, 37:5079–5079. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5079.
    Full Text
  - Halabi, Susan, Sandipan Dutta, John C. Araujo, Christopher Logothetis, Cora N. Sternberg, Andrew J. Armstrong, Michael Anthony Carducci, et al. “External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 37:5022–5022. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5022.
    Full Text
  - Halabi, Susan, Sandipan Dutta, Kim N. Chi, Catherine M. Tangen, Mengdi Xuan, Daniel Peter Petrylak, John C. Araujo, et al. “PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 37:5021–5021. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5021.
    Full Text
  - Morris, Michael J., Glenn Heller, Alan Haruo Bryce, Andrew J. Armstrong, Himisha Beltran, Olwen Mary Hahn, Eric C. McGary, et al. “Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 37:5008–5008. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5008.
    Full Text
  - Prizment, Anna, Susan Halabi, Sean McSweeney, Amy Eisenberg, Arpit Rao, Shilpa Gupta, Alicia K. Morgans, and Charles J. Ryan. “Association of disease prognostic model (PM) with baseline quality of life (QOL) in metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 37:e16579–e16579. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e16579.
    Full Text
  - Rosenberg, Jonathan E., Karla V. Ballman, Susan Halabi, Colleen Watt, Olwen Mary Hahn, Preston D. Steen, Robert Dreicer, et al. “CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.” In Journal of Clinical Oncology, 37:4503–4503. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.4503.
    Full Text
  - Halabi, Susan, Sandipan Dutta, Kim N. Chi, Catherine M. Tangen, Daniel Peter Petrylak, John C. Araujo, Karim Fizazi, et al. “Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 37:186–186. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.186.
    Full Text
  - Al Baghdadi, T., S. Halabi, E. Garrett-Mayer, P. K. Mangat, E. R. Ahn, V. Sahai, R. H. Alvarez, et al. “Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study.” In Jco Precision Oncology, Vol. 3, 2019. https://doi.org/10.1200/PO.19.00124.
    Full Text
  - Koontz, B. F., K. E. Hoffman, P. Healy, D. J. George, M. R. Harrison, T. Zhang, W. R. Lee, et al. “Two Year Outcomes of Short-Term Potent Androgen Blockade and Definitive Radiation for Intermediate to High Risk Localized Prostate Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 102:S100–S100. Elsevier BV, 2018. https://doi.org/10.1016/j.ijrobp.2018.06.256.
    Full Text
  - George, D. J., A. J. Pantuck, R. Figlin, B. Escudier, S. Halabi, M. Casey, X. Lin, L. Serfass, M. J. Lechuga Frean, and A. Ravaud. “Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial.” In Ann Oncol, 29 Suppl 8:viii312, 2018. https://doi.org/10.1093/annonc/mdy283.090.
    Full Text Link to Item
  - Ryan, C. J., S. Dutta, W. Kelly, M. J. Morris, M. -. E. Taplin, and S. Halabi. “Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B).” In Ann Oncol, 29 Suppl 8:viii283, 2018. https://doi.org/10.1093/annonc/mdy284.025.
    Full Text Link to Item
  - George, Daniel J., Elisabeth I. Heath, A Oliver Sartor, Guru Sonpavde, William R. Berry, Patrick Healy, Carolyn Winters, et al. “Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).” In Journal of Clinical Oncology, Vol. 36. AMER SOC CLINICAL ONCOLOGY, 2018.
    Link to Item
  - Al Baghdadi, Tareq, Susan Halabi, Elizabeth Garrett-Mayer, Pam K. Mangat, Eugene R. Ahn, Vaibhav Sahai, Ricardo H. Alvarez, et al. “Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” In Journal of Clinical Oncology, 36:2532–2532. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.2532.
    Full Text
  - Armstrong, Andrew J., Santosh Gupta, Patrick Healy, Gabor Kemeny, Lauren Beth Leith, Michael Zalutsky, Charles Spritzer, et al. “Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.” In Journal of Clinical Oncology, 36:5029–5029. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5029.
    Full Text
  - Armstrong, Andrew J., Susan Halabi, Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Zelig Szmulewitz, Daniel Costin Danila, et al. “The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).” In Journal of Clinical Oncology, 36:5004–5004. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5004.
    Full Text
  - Armstrong, Andrew J., Santosh Gupta, Patrick Healy, Gabor Kemeny, Lauren Beth Leith, Michael Zalutsky, Charles Spritzer, et al. “Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.” In Journal of Clinical Oncology, 36:160–160. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.160.
    Full Text
  - George, Daniel J., Colin Hessel, Susan Halabi, Ben L. Sanford, M Dror Michaelson, Olwen Mary Hahn, Meghara K. Walsh, et al. “Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.” In Journal of Clinical Oncology, 36:582–582. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.582.
    Full Text
  - Koontz, Bridget F., Karen E. Hoffman, Patrick Healy, Daniel J. George, Michael Roger Harrison, Tian Zhang, W Robert Lee, et al. “Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.” In Journal of Clinical Oncology, 36:11–11. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.11.
    Full Text
  - Beltran, Himisha, Alexander W. Wyatt, Edmund C. Chedgy, Adam Donoghue, Matti Annala, Evan W. Warner, Kevin Beja, et al. “Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.” In Clin Cancer Res, 23:6802–11, 2017. https://doi.org/10.1158/1078-0432.CCR-17-1034.
    Full Text Link to Item
  - Choueiri, T. K., C. Hessel, S. Halabi, B. Sanford, O. Hahn, M. D. Michaelson, M. Walsh, et al. “Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC).” In Annals of Oncology, Vol. 28. OXFORD UNIV PRESS, 2017.
    Link to Item
  - Armstrong, Andrew J., Susan Halabi, Patrick Healy, Joshi J. Alumkal, Carolyn Winters, Julie Kephart, Rhonda L. Bitting, et al. “Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.” In Eur J Cancer, 81:228–36, 2017. https://doi.org/10.1016/j.ejca.2017.02.030.
    Full Text Link to Item
  - George, Daniel J., Susan Halabi, Mark D. Starr, Herbert Hurwitz, John C. Brady, Ian Barak, Michael J. Morris, et al. “Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).” In Journal of Clinical Oncology, 35:4522–4522. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.4522.
    Full Text
  - Ryan, Charles J., Sandipan Dutta, William Kevin Kelly, Rob Middleberg, Carly Russell, Eric Jay Small, Michael J. Morris, Mary-Ellen Taplin, and Susan Halabi. “Serum androgens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance).” In Journal of Clinical Oncology, 35:5067–5067. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.5067.
    Full Text
  - Slovin, Susan F., Karen E. Knudsen, Susan Halabi, Emily Carbone, Celina Fernandez, Yu Chen, Karen A. Autio, et al. “Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy.” In Journal of Clinical Oncology, 35:5034–5034. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.5034.
    Full Text
  - Halabi, Susan, and Sandipan Dutta. “Two new residuals in survival analysis with full likelihood.” In Trials, Vol. 18. BIOMED CENTRAL LTD, 2017.
    Link to Item
  - Armstrong, Andrew J., Michael S. Humeniuk, Patrick Healy, Russell Szmulewitz, Carolyn Winters, Julie Kephart, Michael R. Harrison, et al. “Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.” In Prostate, 77:385–95, 2017. https://doi.org/10.1002/pros.23277.
    Full Text Link to Item
  - Choueiri, T. K., S. Halabi, B. Sanford, O. Hahn, M. D. Michaelson, M. Walsh, T. Olencki, et al. “CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial.” In Annals of Oncology, 27:vi566, 2016. https://doi.org/10.1093/annonc/mdw435.23.
    Full Text
  - Xie, W., C. Sweeney, M. Regan, M. Nakabayashi, M. Buyse, N. Clarke, L. Collette, et al. “Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP).” In Annals of Oncology, Vol. 27. OXFORD UNIV PRESS, 2016. https://doi.org/10.1093/annonc/mdw372.1.
    Full Text Link to Item
  - Patel, Jai N., Chen Jiang, Kouros Owzar, Daniel L. Hertz, Flora A. Mulkey, William K. Kelly, Susan Halabi, et al. “Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance).” In Experimental and Molecular Therapeutics. American Association for Cancer Research, 2016. https://doi.org/10.1158/1538-7445.am2016-2037.
    Full Text
  - Slovin, Susan F., Karen E. Knudsen, Emily Carbone, Abosede Showunmi, Melanie Hullings, Michael J. Morris, Karen A. Autio, et al. “Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 34:TPS5093–TPS5093. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.tps5093.
    Full Text
  - Sweeney, Christopher, Wanling Xie, Meredith M. Regan, Mari Nakabayashi, Marc E. Buyse, Noel W. Clarke, Laurence Collette, et al. “Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP).” In Journal of Clinical Oncology, 34:5023–5023. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.5023.
    Full Text
  - Armstrong, A. J., S. Halabi, P. Healy, W. R. Lee, B. F. Koontz, J. W. Moul, K. Mundy, et al. “A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.” In Prostate Cancer and Prostatic Diseases, 19:100–106, 2016. https://doi.org/10.1038/pcan.2015.59.
    Full Text
  - George, Daniel J., Susan Halabi, Patrick Healy, Sarah Gemberling, Carolyn Winters, Kelly Mundy, Michael Roger Harrison, Russell Zelig Szmulewitz, and Andrew J. Armstrong. “Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 34:275–275. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.275.
    Full Text
  - Armstrong, Andrew J., Samuel Broderick, Tim Eisen, Walter Michael Stadler, Robert J. Jones, Jorge A. Garcia, Ulka N. Vaishampayan, et al. “Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Scher, Howard I., Michael J. Morris, Walter Michael Stadler, Celestia S. Higano, Susan Halabi, Matthew Raymond Smith, Ethan M. Basch, et al. “The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).” In Journal of Clinical Oncology, 33:5000–5000. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.5000.
    Full Text
  - Kim, Hyung, Susan Halabi, Ping Li, Greg Mayhew, Jeff Simko, Andrew Nixon, Eric Small, et al. “MP44-01 A PROGNOSTIC MODEL FOR OVERALL SURVIVAL IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CARCINOMA: RESULTS FROM CALGB 90206 (ALLIANCE).” In Journal of Urology, Vol. 193. Ovid Technologies (Wolters Kluwer Health), 2015. https://doi.org/10.1016/j.juro.2015.02.1543.
    Full Text
  - Patel, Jai N., Chen Jiang, Daniel L. Hertz, Flora A. Mulkey, Paula N. Friedman, Susan Halabi, Mark J. Ratain, et al. “Abstract 3841: Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE).” In Clinical Research (Excluding Clinical Trials). American Association for Cancer Research, 2014. https://doi.org/10.1158/1538-7445.am2014-3841.
    Full Text
  - Halabi, Susan, William Kevin Kelly, Haojin Zhou, Andrew J. Armstrong, David Quinn, Karim Fizazi, Nicole C. Solomon, et al. “The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.” In Journal of Clinical Oncology, 32:5002–5002. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5002.
    Full Text
  - Hertz, Daniel Louis, Chen Jiang, Kouros Owzar, Susan Halabi, William Kevin Kelly, Flora Mulkey, Jai Narendra Patel, et al. “A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).” In Journal of Clinical Oncology, 32:9612–9612. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.9612.
    Full Text
  - Kluger, Harriet M., Susan Halabi, Nicole C. Solomon, Lucia Jilaveanu, Christopher Zito, Joshua Sznol, Andrew B. Nixon, Brian I. Rini, Eric Jay Small, and Daniel J. George. “Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.” In Journal of Clinical Oncology, 32:4532–4532. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.4532.
    Full Text
  - Patel, Jai Narendra, Chen Jiang, Daniel Louis Hertz, Flora Mulkey, Paula N. Friedman, Susan Halabi, Mark J. Ratain, et al. “Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).” In Journal of Clinical Oncology, 32:e16061–e16061. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e16061.
    Full Text
  - Halabi, S., C. Y. Lin, W. K. Kelly, K. Fizazi, J. W. Moul, E. Kaplan, M. J. Morris, and E. J. Small. “A validated prognostic model for predicting overall survival in patients with metastatic chemotherapy naive castrate-resistant prostate cancer.” In European Journal of Cancer, 49:S679–S679. ELSEVIER SCI LTD, 2013.
    Link to Item
  - Armstrong, Andrew J., Susan Halabi, Tim Eisen, Walter Michael Stadler, Robert R. Jones, Ultra N. Vaishampayan, Jorge A. Garcia, et al. “ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Bitting, Rhonda Lynn, Patrick Healy, Susan Halabi, Daniel J. George, Jung Hyun Ko, and Andrew J. Armstrong. “Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Halabi, Susan, Chen-Yen Lin, Eric Jay Small, Andrew J. Armstrong, Ellen B. Kaplan, Daniel Peter Petrylak, Cora N. Sternberg, et al. “A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Hertz, Daniel Louis, Kouros Owzar, Susan Halabi, William Kevin Kelly, Hitoshi Zembutsu, Chen Jiang, Jai Narendra Patel, et al. “A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Mahar, Alyson L., Susan Halabi, Lisa M. McShane, Patricia A. Groome, and Carolyn C. Compton. “A survey of clinical prediction took in colorectal and lung cancers and melanoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Nixon, Andrew B., Susan Halabi, Ivo Shterev, Mark Starr, John C. Brady, Janice P. Dutcher, Judith O. Hopkins, et al. “Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Armstrong, Andrew J., Tong Shen, Susan Halabi, Gabor Kemeny, Rhonda Lynn Bitting, Patricia Kartcheske, Elizabeth Embree, et al. “A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.” In Journal of Clinical Oncology, 31:105–105. American Society of Clinical Oncology (ASCO), 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.105.
    Full Text
  - Halabi, Susan, Chen-Yen Lin, Eric Jay Small, Andrew J. Armstrong, Ellen B. Kaplan, Daniel Peter Petrylak, Cora N. Sternberg, et al. “A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.24.
    Full Text Link to Item
  - Smith, Matthew Raymond, Susan Halabi, Charles J. Ryan, Walter Michael Stadler, Arif Hussain, Nicholas J. Vogelzang, Ralph J. Hauke, Ben L. Sanford, and Eric Jay Small. “Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance).” In Journal of Clinical Oncology, 31:27–27. American Society of Clinical Oncology (ASCO), 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.27.
    Full Text
  - Apolo, Andrea Borghese, George Philips, Irina Ostrovnaya, Jonathan E. Rosenberg, Matthew I. Milowsky, Eric Jay Small, Dean F. Bajorin, and Susan Halabi. “External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Halabi, Susan, Andrew J. Armstrong, A Oliver Sartor, Johann Sebastian De Bono, Ellen B. Kaplan, and Eric Jay Small. “Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Kelly, William Kevin, Susan Halabi, Michael Anthony Carducci, Daniel J. George, John Francis Mahoney, Walter Michael Stadler, Michael J. Morris, Philip W. Kantoff, J. P. Monk, and Eric Jay Small. “Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Small, Eric Jay, Susan Halabi, Michael Anthony Carducci, Charles J. Ryan, Daniel J. George, John Francis Mahoney, Walter Michael Stadler, et al. “The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Halabi, Susan, William Kevin Kelly, Ellen B. Kaplan, and Eric Jay Small. “Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 30:200–200. American Society of Clinical Oncology (ASCO), 2012. https://doi.org/10.1200/jco.2012.30.5_suppl.200.
    Full Text
  - George, D. J., S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, et al. “Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium.” In Journal of Clinical Oncology, 29:4664–4664. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.4664.
    Full Text
  - Hurwitz, M., S. Halabi, L. Archer, L. S. McGinnis, M. R. Kuettel, S. J. DiBiase, and E. J. Small. “Combination External Beam Radiation and Brachytherapy Boost with Androgen Suppression for Treatment of Intermediate-risk Prostate Cancer: Long-term Results of CALGB 99809.” In International Journal of Radiation Oncology*Biology*Physics, 78:S146–S146. Elsevier BV, 2010. https://doi.org/10.1016/j.ijrobp.2010.07.362.
    Full Text
  - Rini, B. I., S. Halabi, J. Rosenberg, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czaykowski, J. Dutcher, and E. J. Small. “First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Rini, B. I., S. Halabi, J. Rosenberg, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czaykowski, J. Dutcher, and E. J. Small. “Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Armstrong, A. J., S. Halabi, I. F. Tannock, D. J. George, R. Dewit, and M. Eisenberger. “Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Halabi, S., O. Sartor, D. Petrylak, C. N. Sternberg, J. A. Witjes, M. Noursalehi, T. J. McKearn, and M. J. George. “Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Luu, T., O. Sartor, N. Dandade, S. Halabi, and C. Bennett. “Comparability of health-related quality of life (HRQOL), treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy (HT) versus observation (OBS): Results from the COMPARE registry.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Rini, B. I., S. Halabi, J. Rosenberg, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czaykowski, J. Dutcher, and E. J. Small. “Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Sartor, A. O., D. Petrylak, C. Sternberg, F. Witjes, S. Halabi, W. Berry, M. Petrone, T. McKearn, M. Noursalehi, and M. George. “Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial.” In Journal of Clinical Oncology, Vol. 27, 2009.
    Link to Item
  - D’Amico, A. V., S. Halabi, R. Vollmer, M. Loffredo, E. McMahon, B. Sanford, L. Archer, N. J. Vogelzang, E. Small, and P. Kantoff. “p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study.” In International Journal of Radiation Oncology*Biology*Physics, 69:S333–S333. Elsevier BV, 2007. https://doi.org/10.1016/j.ijrobp.2007.07.1406.
    Full Text
  - D’Amico, A. V., S. Halabi, C. Tempany, R. Vollmer, M. Loffredo, B. Sanford, and E. J. Small. “Changes on endorectal MRI during neoadjuvant hormonal therapy for prostate cancer and biochemical outcome in men managed using radiation therapy: A prospective phase II Cancer and Leukemia Group B study.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Halabi, S., S. Ou, N. J. Vogelzang, H. Scher, and E. J. Small. “A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer (CRPC).” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Scher, H. I., S. Halabi, I. Tannock, M. Morris, C. Higano, W. Kelly, C. Sternberg, M. Eisenberger, A. Martin, and M. Hussain. “The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Hurwitz, M. D., S. Halabi, S. S. Ou, L. S. McGinnis, M. R. Keuttel, S. J. DiBiase, and E. J. Small. “2230.” In International Journal of Radiation Oncology*Biology*Physics, 66:S337–38. Elsevier BV, 2006. https://doi.org/10.1016/j.ijrobp.2006.07.636.
    Full Text
  - Halabi, S., S. Ou, N. J. Vogelzang, and E. J. Small. “An elevated body mass (BMI) index predicts far better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC).” In Journal of Clinical Oncology, 24:230S-230S. AMER SOC CLINICAL ONCOLOGY, 2006.
    Link to Item
  - Philips, G., B. Sanford, S. Halabi, D. Bajorin, and E. J. Small. “Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102.” In Journal of Clinical Oncology, 24:236S-236S. AMER SOC CLINICAL ONCOLOGY, 2006.
    Link to Item
  - Picus, J., S. Halabi, E. Small, A. Hussain, G. Philips, E. Kaplan, and N. Vogelzang. “Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782.” In Journal of Clinical Oncology, 24:234S-234S. AMER SOC CLINICAL ONCOLOGY, 2006.
    Link to Item
  - Rosenberg, J. E., S. Halabi, B. L. Sanford, A. L. Himelstein, J. N. Atkins, R. Hohl, S. L. Seagren, D. F. Bajorin, and E. J. Small. “CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC).” In Journal of Clinical Oncology, 24:237S-237S. AMER SOC CLINICAL ONCOLOGY, 2006.
    Link to Item
  - Sartor, O., C. L. Bennett, S. Halabi, M. Kattan, and P. Scardino. “Race/ethnicity, literacy, and prostate cancer: Initial findings from the COMPARE registry.” In Journal of Clinical Oncology, 24:246S-246S. AMER SOC CLINICAL ONCOLOGY, 2006.
    Link to Item
  - Schildkraut, Joellen M., Amy French, Brian Calingaert, Rex C. Bentley, Susan Murphy, Jeffrey R. Marks, Patricia Moorman, Susan Halabi, and Andrew Berchuck. “Molecular epidemiology of cyclin E overexpression in epithelial ovarian cancer.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.
    Link to Item
  - Dawson, N. A., S. Halabi, D. D. Biggs, S. S. Ou, W. K. Kelly, and E. J. Small. “A phase II study of estramustine (E), docetaxel (D) and exisulind in hormonerefractory prostate cancer (HRPC): Initial results of CALGB 90004.” In Journal of Clinical Oncology, 23:415S-415S. AMER SOC CLINICAL ONCOLOGY, 2005.
    Link to Item
  - Garber, J. E., S. Halabi, E. Kaplan, S. Edge, L. Dressler, E. Paskett, and N. Berliner. “Factor V leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen.” In Journal of Clinical Oncology, 23:6S-6S. AMER SOC CLINICAL ONCOLOGY, 2005.
    Link to Item
  - Halabi, S., E. J. Small, S. Ou, and N. J. Vogelzang. “The impact of age on clinical outcomes in men with hormone refractory prostate cancer.” In Journal of Clinical Oncology, 23:408S-408S. AMER SOC CLINICAL ONCOLOGY, 2005.
    Link to Item
  - Rini, Brian I., Susan Halabi, Robert Barrier, Kim A. Margolin, David Avigan, Theodore Logan, Philip L. McCarthy, Eric S. Small, and Charles A. Linker. “CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.” In Blood, 104:810–810. American Society of Hematology, 2004. https://doi.org/10.1182/blood.v104.11.810.810.
    Full Text
  - Schildkraut, J. M., A. Berchuck, S. Murphy, J. Marks, P. Moorman, B. Calingaert, and S. Halabi. “Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer.” In Cancer Epidemiology Biomarkers & Prevention, 13:1897S-1897S. AMER ASSOC CANCER RESEARCH, 2004.
    Link to Item
  - D’Amico, A. V., S. Halabi, N. J. Vogelzang, and E. J. Small. “A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials.” In Journal of Clinical Oncology, 22:383S-383S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Halabi, S., E. J. Small, T. Gilligian, R. Barrier, S. George, and N. J. Vogelzang. “The effect of race on progression-free survival in patients with metastatic hormone-refractory prostate cancer (HRPC): A pooled analysis of CALGB studies.” In Journal of Clinical Oncology, 22:400S-400S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Humphrey, P., S. Halabi, J. Picus, N. Vogelzang, E. Small, and P. Kantoff. “Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480.” In Journal of Clinical Oncology, 22:863S-863S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Philips, G., S. Halabi, B. Sanford, D. Bajorin, and E. Small. “Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102.” In Journal of Clinical Oncology, 22:391S-391S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Picus, J., S. Halabi, E. Small, A. Hussain, G. Philips, E. Kaplan, and N. Vogelzang. “Efficacy of peripheral androgen blockade on prostate cancer: Results of CALGB 9782.” In Journal of Clinical Oncology, 22:396S-396S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Ryan, C. H., S. Halabi, E. Kaplan, N. Vogelzang, P. Kantoff, and E. J. Small. “Use of adrenal androgen levels to predict response to ketoconazole in patients with androgen independent prostate cancer: Results from CALGB 9583.” In Journal of Clinical Oncology, 22:396S-396S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Stadler, W. M., S. Halabi, M. S. Ernstoff, R. Barrier, E. Davila, J. Picus, and E. J. Small. “A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008.” In Journal of Clinical Oncology, 22:385S-385S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Taplin, M. E., D. J. George, S. Halabi, W. R. Sellers, B. Sanford, K. T. Hennessy, G. G. Mihos, E. J. Small, and P. W. Kantoff. “Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated an Cancer and Leukemia Group B (CALGB) 9480.” In Journal of Clinical Oncology, 22:396S-396S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Schildkraut, J. M., R. Wenham, J. Lancaster, B. Calingaert, K. McLean, S. Halabi, J. Marks, and A. Berchuck. “A case-control study of candidate ovarian cancer susceptibility polymorphisms.” In Cancer Epidemiology Biomarkers & Prevention, 11:1165S-1165S. AMER ASSOC CANCER RESEARCH, 2002.
    Link to Item
Teaching & Mentoring
Recent Courses
- CRP 248: Clinical Trials 2020
- CRP 248: Clinical Trials 2019
- CRP 248: Clinical Trials 2018
Teaching Activities
- CRP 245

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

In the News

Awards & Honors

Subject Headings

Global Scholarship

Research

Selected Grants

External Relationships

Selected Publications

Academic Articles

Book Sections

Conference Papers

Recent Courses

Teaching Activities